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I. Bone tumors
Bone sarcomas are rare neoplasms with an incidence of around the 1-2 new cases per 100.000
individuals per year. The most common primary malignant bone tumors are osteosarcomas,
followed by chondrosarcomas and Ewing sarcomas. Both osteosarcomas and Ewing sarcomas
have the highest incidence in younger patients, up to twenty years of age, whereas
chondrosarcomas are more prevalent at around the second to fourth decade of life (Table
1.1).
Clinical features of bone tumors are often non-specific, and as a consequence of this they
often are not detected in the early phases. Symptoms pointing to bone tumors are pain, swelling
and a general discomfort. They can also be detected through spontaneous fractures, as a
consequence of the fact that the bone structure is altered by the tumor.
II. Chondrosarcoma
Chondrosarcomas are, after osteosarcomas, the most prevalent bone sarcomas. They are
characterized by the production of cartilage instead of bone. The incidence in males and
females is equal, and it mainly occurs in adults of 30-60 years [1]. Most of these tumors
occur in the long bones. Within the group of chondrosarcomas different subtypes are discerned
[2-4] (Table 1.2).
Conventional central chondrosarcomas can arise de novo in the medulla of the bone (primary),
or from an enchondroma (secondary) [5]. This group comprises about 80% of all conventional
chondrosarcomas. The second most prevalent chondrosarcomas are the secondary peripheral
chondrosarcomas, which per definition arise in the cartilage cap of an osteochondroma [6].
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Osteochondroma is a cartilage-capped bony projection arising on the external surface of
bone, and contains a marrow cavity that is continuous with that of the underlying bone [7].
The cartilage is organized histologically in the same manner as the normal human growth
plate. In enchondromas no specific growth pattern is discerned. The peripheral and central
chondrosarcomas look histologically similar and in both three grades of malignancy are
discerned (Table 1.3; Figure 1.1) [2].
Grading is one of the most important prognostic predictors. In high-grade tumors the risk of
metastasis is increased. Where as grade I chondrosarcomas seldom metastasize, 10-33% of
grade II and ~70% of grade III chondrosarcomas metastasize [2,8]. However, this method of
grading is somewhat subjective and therefore it would be helpful to find a molecular marker
predicting outcome. Apart from grading also the localization is of importance for prognosis,
as is summarized in chapter 2.
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III. Conventional central chondrosarcoma
About 80% of the conventional chondrosarcomas are originating centrally in the medulla
cavity of the bone central. In contrast to enchondromas that frequently occur in the small
bones of hands and feet, chondrosarcomas are extremely rare at this phalangeal localization.
The most prominent affected sites are femur (30%), pelvis (30%) and humerus (15%) [1]. In
the literature the incidence of secondary central chondrosarcomas varies significantly, ranging
from 1-2 % to 40% [3,9] depending on if one requires evidence of a pre-existing enchondroma
or evidence of an enchondroma next to a chondrosarcoma (see also chapter 2).
Genetics of conventional central chondrosarcoma
Little is known regarding the way conventional central chondrosarcomas arise and only few
studies have been performed that make the distinction between central and peripheral
chondrosarcomas. Most central chondrosarcomas are near-diploid [10]. Genetic studies
revealed only few genomic alterations in enchondromas and low-grade central
chondrosarcomas. In high-grade central chondrosarcomas more complex aberrations are found
[11,12]. However, most alterations appear to be random. Studies using cytogenetics, loss of
heterozygosity (LOH) or mutational analysis revealed that some chromosomes or
chromosomal regions seem to be non-randomly affected. Structural alterations of chromosome
9, mainly focused on 9p, seem to be more common in for central chondrosarcomas [10].
Chromosomal region 9p12-22, which was found to be targeted in at 3 of 12 central
chondrosarcomas, contains the tumor suppressor gene CDKN2A, also known as p16 [10].
This gene is deleted in several types of cancer and could therefore be a candidate gene for
central chondrosarcomas. Also band 17p13, containing the tumor suppressor TP53, has been
studied and loss or mutations were identified, mainly in high-grade tumors. Without
distinguishing central and peripheral chondrosarcomas, loss of chromosome arms 6q, 10p,
11p, 11q or 22q seemed to correlate with grade and loss of 13q was found to be a prognostic
factor for metastasis [12].
Figure 1.1: Histology chondrosarcoma grade I (A), II (B), and III (C)
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Protein expression studies
Immunohistochemistry studies on chondrosarcomas have been done quite extensively. In
most cases again no distinction was made between central and peripheral chondrosarcomas
and prognostic factors were not found (summarized in chapter 2).
IV. Enchondroma
Enchondroma is the benign counterpart of central conventional chondrosarcomas. The
incidence of enchondromas is not known, since they often are asymptomatic, and only found
after a fracture or bone scans on other grounds, such as screening for some metastasis of
epithelial cancer. The risk of malignant transformation is <1%.
Histologically, the distinction between enchondroma and chondrosarcoma is mainly based
on comparison of cytology, architecture and growth patterns. Whereas the enchondromas
are often encased by normal lamellar bone at the outside of the tumor (encasement),
chondrosarcomas show infiltration of tumor tissue in the normal bone (entrapment) [9,13].
However, the distinction is not always easy and molecular markers for diagnostic purposes
would be helpful.
Radiological analysis is helpful in making the distinction between enchondromas and
chondrosarcomas. Plain X-ray is unable to make this distinction [14], whereas magnetic
resonance (MR) improves tissue characterization of cartilaginous tumors and may assist in
identifying low-grade chondrosarcoma. Gadolinium-enhanced MR can be used [15], but
better results are obtained using fast contrast-enhanced MR imaging, that may assist in
differentiation between benign and malignant cartilaginous tumors in adults [16].
V. Enchondromatosis
While most enchondromas and/or conventional central chondrosarcomas are solitary, some
occur multiple in the context of a syndrome (enchondromatosis) [17]. The two best known
are Ollier disease [18,19], characterized by the presence of multiple enchondromas, and
Maffucci syndrome [20], characterized by the presence of multiple enchondromas and
Figure 1.2: Radiographs of hands from 2 patients with enchondromatosis. A) Hand from patient with Ollier disease
with multiple enchondromas, B) Hand from patient with Maffucci syndrome, containing enchondromas and calcified
thrombi in soft tissue haemangiomas. Source: Committee on Bone Tumors, The Netherlands
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haemangiomas (benign vascular lesions) (Figure 1.2). None of the syndromes is hereditary,
though rare cases in which more than one person in the family is affected have been reported.
In patients with enchondromatosis it is frequently seen that only one side of the body is
affected. This could point in the direction of an early mutation event in embryogenesis,
resulting in mosaicism.
Patients with enchondromatosis have an increased risk of malignant transformation and the
chance of developing a chondrosarcoma can be as high as 35%, compared to < 1% in patients
with a solitary enchondroma [17]. Enchondromas in patients with enchondromatosis behave
less aggressively and slightly different criteria for malignancy are thus applied: more
worrisome features are accepted in enchondromas [17] from patients with enchondromatosis,
such as increased cellularity and more cytological atypia.
Genetics
Genetic studies on enchondromatosis tumor samples are rare. LOH of chromosomal regions
13q14 and 9p21 [21] were found in a chondrosarcoma of one patient and deletion of 1p in
another patient [22]. Also a mutation in the PTHR1 gene, called p.R150C PTHR1, has been
described in two of six patients with Ollier disease, one as a germline mutation and one most
likely somatic [23].
In addition to the well-known syndromes, Ollier disease and Maffucci syndrome, some other,
less well-defined subtypes of enchondromatosis have been described:
1) Spondyloenchondromatosis / spondyloenchondrodysplasia
Spondyloenchondromatosis [24-27] is a syndrome defined by the presence of multiple
enchondromas and the presence of platyspondyly (flattened vertebral body shape with reduced
distance between the endplates). The patients have short stature, short trunk, and short limbs,
and the hands and feet are only mildly involved. In contrast to Ollier disease and Maffucci
syndrome spondyloenchondromatosis is thought to be hereditary, following an autosomal
recessive pattern.
2) Metachondromatosis
Metachondromatosis [28] is characterized by a combination of multiple enchondromas and
osteochondromas. It follows an autosomal dominant inheritance pattern.
3) Generalized enchondromatosis
Generalized enchondromatosis [29,30] is described by evenly distributed enchondromas with
severe involvement of hands and feet, mild platyspondyly and skull deformity. It was found
to be familial in one case, following an autosomal recessive pattern.
4) Others
Other subtypes have been described, and they are subdivided based upon varying involvement
of hands and feet, platyspondyly or vertebral lesions [26,30,31].
VI. Phalangeal enchondromas and chondrosarcomas
Most enchondromas are located in the long bones and about 50% of these tumors are found
in the hands and feet [32,33], where they most frequently involve the proximal phalanx,
followed by the middle phalanx, and the metacarpals. In these cases deformations may arise.
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Conventional central chondrosarcomas of the phalanx are extremely rare and they only rarely
metastasize (<2%)[34]. Therefore, a different histological cut-off between enchondroma and
low-grade chondrosarcoma is applied to these tumors. Thus, enchondromas of the phalanx
can look histologically like a chondrosarcoma, but are still diagnosed as enchondromas
because of the phalangeal localization. However, the reason for this favorable outcome of
phalangeal chondrosarcomas is not known. Either these tumors are biologically different or
the location (and smaller size of these tumors due to early detection, different vascularization
or lower temperature) could account for their low property to metastasize [34,35].
VII. IHH/PTHLH signaling
The pathogenesis of enchondromas and central chondrosarcomas is not known. It has been
suggested that they arise from cartilage residues of the growth plate. In the normal growth
plate a tight signal regulation takes place, organizing the proliferation and differentiation of
the chondrocytes. One of the important signaling pathways is the Indian Hedgehog/
Parathyroid Hormone Like Hormone IHH/PTHLH negative feedback loop [36,38,50-52]
(Figure 1.3). This signaling pathway is suggested to be altered in tumors of patients with
Figure 1.3: IHH/PTHLH signaling in the postnatal growth plate. Chondrocytes in the transition zone secrete
Indian Hedgehog (IHH) protein, which diffuses to its receptor Patched (PTCH) in the hypertrophic zone. This
increases secretion of Parathyroid Hormone Like Hormone (PTHLH), located in the hypertrophic zone [36],
which diffuses to its receptor. Terminal differentiation is inhibited by direct or indirect upregulation of BCL2,
prolonging cell survival [37]. In this way, PTHLH regulates chondrocyte differentiation by delaying the progression
of chondrocytes towards the hypertrophic zone and allowing longitudinal bone growth [38]. EXT1 and EXT2 are
expressed in the proliferative and transition zone [39] and are required for the formation of Heparan sulphate
proteoglycans (HSPGs), expressed in all zones of the growth plate [40-45]. HSPGs play a role in the high affinity
binding of ligands to their receptor and possibly the diffusion of the molecules. High affinity binding of the ligand
FGF18 [46] to the receptor (FGFR3, but also FGFR1 and FGFR2), expressed in the proliferation zone, requires
HSPGs. Upon binding cyclin-dependent kinase inhibitor 1A (CDKN1A, p21) is activated [47], inhibiting chondrocyte
proliferation, and thereby the IHH expressing cells [48].
Adapted from L. Hameetman et al [49].
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multiple osteochondromas, a hereditary syndrome caused by mutations in the EXT genes
(see chapter 2).
Binding of IHH to its receptor PTCH will result in the release of Smoothened (SMOH) by
PTCH. Now the transcription factors GLI-Kruppel family members 1-3 (GLI1-3) are stabilized
and transcription of several genes including PTCH, GLI1-3 and Cyclin E (CCNE) is
upregulated [51,53]. Downstream of IHH PTHLH (PTHrP) signaling is found. This signaling
regulates the pace of chondrocytes differentiation by delaying the progression of chondrocytes
towards the hypertrophic zone, allowing longitudinal bone growth [38] completing the
negative feedback loop. In addition, the transition from G1 to S phase is a crucial step in the
growth and is regulated by, amongst others, Cyclin D1, Cyclin E and p21 (CDKN1A). In
chondrocytes this transition is partly influenced by IHH (Cyclin E) and PTHR1 (Cyclin D1)
[50-52].
VII. Aim of the study and outline of the thesis
Enchondromas and conventional central chondrosarcomas are cartilage producing bone tumors
as outlined above. Among these tumors two differently behaving subtypes are discerned,
enchondromatosis-related and phalangeal enchondromas/chondrosarcomas.
The purposes of the studies presented in this thesis were to:
further elucidate the multi-step genetic model in central chondrosarcoma.
by identifying the molecular change(s) underlying malignant transformation of enchondroma
we aim at finding molecular markers that may aid in the difficult differential diagnosis between
enchondromas and low-grade chondrosarcomas.
1) by identifying the molecular change(s) involved in the progression from low-grade
towards high-grade chondrosarcoma we hope to find prognostic markers, independent
of histological grade. This is of interest since progression of grade can be observed with
recurrent chondrosarcomas. In this thesis we looked at progression by comparing primary
chondrosarcomas of different grades to each other.
2) investigate if there are molecular differences between enchondromatosis-related tumors
and solitary tumors, to see if we can identify the molecular defect underlying
enchondromatosis and further understand the less aggressive behavior of enchondromas
in patients with enchondromatosis. We looked genome wide both at RNA expression
levels and genomic aberrations. In addition a more hypothesis-driven approach was
chosen, based on the IHH and PTHLH signaling pathways. These pathways are involved
in normal cartilage growth and differentiation, which are though to play a role in
osteochondromas and secondary peripheral chondrosarcomas and was alleged to be
affected in Ollier disease.
investigate if there is a biological difference between phalangeal enchondromas and
chondrosarcomas compared to enchondromas and chondrosarcomas located elsewhere, since
phalangeal tumors only rarely metastasize, although the histological appearance suggests
malignancy. The reason for this favorable outcome of phalangeal chondrosarcomas is not
known. Either these tumors are biologically different or the location (and smaller size of
these tumors) may be causative for their favorable prognosis.
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Chapter 2 contains a more detailed review regarding the diagnosis and prognosis of both
conventional central chondrosarcomas and secondary peripheral chondrosarcomas. The
genetics of the different subtypes and an inventory of what was known in the literature of
molecular markers for chondrosarcomas at the start of this study are summarized.
Since the loss of chromosomal region 9p21-22 was found more frequently in central
chondrosarcomas as compared to peripheral chondrosarcoma in chapter 3 we investigated
the candidate gene CDKN2A located in 9p21.
In chapter 4 the presence of a reported PTHR1 mutation in patients with enchondromatosis
was investigated. The reported mutation was shown to lead to an upregulation of the IHH/
PTHLH signaling. This was puzzling since in osteochondromas the IHH/PTHLH signaling
is downregulated most likely as a consequence of EXT inactivation.
Chapter 5 describes the expression of the IHH/PTHLH signaling pathway in several subtypes
of enchondromas and conventional central chondrosarcomas. This pathway most likely plays
an important role in osteochondromas and peripheral chondrosarcomas, which closely
resemble central chondrosarcomas. In this article also samples from patients with Ollier
disease and enchondromas and chondrosarcomas of the phalanx were included, to get a more
complete overview of the IHH/PTHLH signaling in the different subtypes
The results of a genome wide approach to unravel central cartilaginous tumorigenesis are
discussed in chapter 6 and 7. In chapter 6 expression profiles found in enchondromas, the
different grades of chondrosarcomas and those present in Ollier disease are compared. The
genomic alterations, studied with a ~1 Mb spaced array CGH, are described in chapter 7 in
which they are combined with array expression studies from chapter 6.
All results are summarized and discussed in chapter 8.
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Diagnosis and prognosis of chondrosarcoma of bone
LB Rozeman, PCW Hogendoorn and JVMG Bovée
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The mechanisms of chondrosarcoma development are just beginning to be unraveled. The
distinction between benign and low-grade malignant cartilaginous tumors is difficult and is
based mainly on radiological and clinicopathological features. In this review, the conventional
chondrosarcomas are subdivided into central and secondary peripheral chondrosarcomas,
based on their different genetic and clinicopathological background. Thus far, no diagnostic
markers have been identified for central tumors. BCL2 is a good diagnostic marker that can
be used in the distinction between osteochondroma and low-grade secondary peripheral
chondrosarcoma. For the prognosis of chondrosarcomas, the best and most commonly used
marker at present is histological grade. Several molecular markers, recapitulated in this paper,
have been tested to see if they aid in determining diagnosis and predicting prognosis, but
most are not independent of histological grade.
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The prevalence of primary malignant bone tumors is estimated 1: 100.000 within the general
population, 17-24% of which are chondrosarcomas [1] .[2] Chondrosarcoma of bone is a
slowly growing malignant tumor characterized by the formation of cartilage instead of bone.
The tumors have an equal sex incidence and principally occur in adults of 30-60 years. Chon-
drosarcomas are found mostly in the long bones (33%), pelvic bones (27%) and in ribs and
scapula (10%). The most adequate treatment is surgery, since the tumors are highly resistant
to chemotherapy and radiotherapy [3]. The final diagnostic assessment is the result of a
multidisciplinary approach involving the clinical, radiological and histopathological data.
Chondrosarcomas can be classified based upon microscopic features. The most common is
conventional chondrosarcoma (80-85%). Dedifferentiated chondrosarcoma (10%), mesen-
chymal chondrosarcoma (2%), juxtacortical chondrosarcoma (2%) and clear cell chondrosa-
rcoma (1%) are rare.
Conventional chondrosarcomas
Conventional chondrosarcomas can be subclassified in two ways. One subdivision is made
between primary (without evidence of a pre-existing benign lesion such as enchondroma or
osteochondroma) and secondary (evidence of a pre-existing benign lesion is present)
chondrosarcomas. Another subdivision can be made according to their location in the bone.
Most chondrosarcomas (83%) arise centrally within the medullary cavity of bone (primary
conventional central chondrosarcomas, or secondary central chondrosarcomas if they develop
from a pre-existing enchondroma), while a minority (17%) consist of secondary peripheral
chondrosarcomas, developing at the surface of bone secondarily within the cartilaginous cap
of a pre-existing osteochondroma (cartilage-capped bony protuberance developing from juxta-
epiphyseal regions of long bones) [2,4].
Both central and secondary peripheral chondrosarcoma have similar cytonuclear features
and three grades of malignancy are discerned [5]. Increasing histological grade is correlated
with an increased risk of metastases and reduced survival time [5,6]. The fact that recurrences
of chondrosarcomas can exhibit a higher grade of malignancy compared to the previous
lesion suggests that these tumors may progress in grade [5,7].
Despite the fact that both central and peripheral chondrosarcomas have similar, if not
indistinguishable, cytonuclear features, they do have a different genetic etiology.
Diagnosis of chondrosarcoma
The distinction between enchondroma or osteochondroma and low-grade chondrosarcoma
is difficult both at the radiological level (in case of central chondrosarcomas) [8] and the
histological level (for both central and peripheral chondrosarcomas) [9,10]. Thus far, the
differential diagnosis between benign and low-grade chondrosarcomas is usually based on a
combination of clinical, radiological and histological features. A correct diagnosis is essential
for selecting therapy. Benign lesions can have a wait-and-see policy - since the risk of
malignant transformation is low (about 1%) - or local treatment. In contrast, complete wide
en bloc excision, which may be mutilating, is required for malignant tumors.
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Radiology
Using (dynamic) magnetic resonance imaging (MRI), a fairly reliable assessment of the
differential diagnosis between osteochondromas and low-grade secondary peripheral
chondrosarcomas can be provided by estimating the thickness and evaluating the characteristic
staining of the cartilaginous cap [11]. For the distinction between enchondromas and low-
grade central chondrosarcomas clinical symptoms and radiographic features are of help but
both lack specificity [8,12,13]. Fast contrast-enhanced MRI can be used to confirm the
difference between benign lesions and all conventional high-grade chondrosarcomas, since
in contrast to benign and borderline cases, high-grade chondrosarcomas have a highly
vascularised pattern [14]. Analogously, at the histological level, enchondromas consist of an
avascular cartilaginous matrix without overt induction of neovascularisation. In contrast,
low-grade chondrosarcomas have a fibrovascular stroma surrounding the avascular
cartilaginous nodules [15,16]. These features thus form the basis for dynamic contrast-
enhanced MRI [14].
Histology
At the histological level, the distinction between enchondroma and low-grade central
chondrosarcoma is mainly based on growth patterns and cytomorphological features. Host-
bone entrapment (defined as the permeation of tumor around preexisting lamellar host bone),
tumor encasement (defined as new shells of lamellar bone at the periphery of cartilage
nodules), high cellularity , marked nuclear pleomorphism an irregular cell distribution are
the main histological determinators [9,16]. The presence of mucoid matrix degeneration in
20% or more of the lesion, and the presence of host-bone entrapment almost certainly indicates
malignancy [16].
Additional techniques
Several studies have been reported on potential markers for distinguishing benign precursor
lesions (enchondroma, osteochondroma) from low-grade chondrosarcomas. Although some
give significant different expression levels for benign and malignant lesions, a problem is
that the distinction between the expression levels may not always be so accurate. Factors
reported to show a significantly increased expression in chondrosarcoma grade I as compared
with their benign counterparts are parathyroid hormone like hormone (PTHLH) and BCL2
[17], both restricted to peripheral tumors [18], and platelet derived growth factor (PDGF)-α
receptor and Ki-67 [19]. These molecular markers may be especially helpful in small biopsies
that are not big enough to assess the growth patterns as described above [9]. No molecular
diagnostic markers are known for the distinction between enchondromas and central
chondrosarcomas.
A major drawback of most molecular genetic reports on chondrosarcomas so far, however, is
that no clear distinction is made between central and secondary peripheral chondrosarcomas.
A distinction is, however, essential because of their different genetic mechanisms of
development. This could mean that potential diagnostic factors that are declared unfit for the
assessment of malignancy, may be important diagnostic factors specifically for central or
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peripheral tumors. The genetics of these two different clinico-pathological subtypes will
therefore be discussed separately.
Central chondrosarcoma
Most chondrosarcomas are central (intramedullary) chondrosarcomas. They can be primary
or they can develop secondarily to a benign precursor lesion, enchondroma, which is estimated
to occur in less than 1% of enchondromas [2]. Most enchondromas are solitary, while in
patients with nonhereditary Ollier disease or Maffucci syndrome, multiple enchondromas
are found, scattered all over the skeleton, often with a unilateral predominance [20]. Maffucci
syndrome is characterized by the simultaneous occurrence of multiple enchondromas and
soft tissue vascular lesions. The percentage of malignant transformation in patients with
Ollier disease or Maffucci syndrome is much greater than for solitary enchondroma and has
been estimated at 25-30% [2,21].
Origin of central chondrosarcomas
There is considerable debate in the literature about the incidence of secondary central
chondrosarcomas and the percentage ranges from 1-2% [2] to approximately 40% [10]. This
wide range is most likely explained by how secondary central chondrosarcoma are defined.
The incidence is low when the definition is applied that a pre-existing enchondroma has to
have been detected previously. A point of discussion is, however, that enchondromas do not
always give complaints and often remain undetected or are only found by chance, for example,
with X-ray after fracture. A much greater incidence of secondary central chondrosarcoma is
found if one defines central chondrosarcomas as secondary when the remains of a pre-existing
enchondroma are present at the time of diagnosis, histologically or radiologically, next to a
central chondrosarcoma [10]. Not all known secondary chondrosarcomas do, however, show
evidence of the previous enchondroma. For example, Brien et al. [10] described a patient
known to have an enchondroma. When the patient returned with complaints, the benign
lesion had transformed into a chondrosarcoma, without it showing any evidence of the pre-
existing enchondroma. This could imply that a substantial number, if not all, central
chondrosarcomas are actually secondary.
Genetics
Not many genetic aberrations are known to be specific for low-grade central chondrosarcomas.
DNA flow cytometry data that make a distinction between central and secondary peripheral
chondrosarcomas show that central chondrosarcomas are predominantly peridiploid [22].
Loss of heterozygosity (LOH), comparative genomic hybridization and karyotyping show
that a broad range of genomic alterations can be found but most are probably random.
However, there are indications that chromosomes 9 and 22 are more often affected (Figure
2.1) [22].
Recently, an activating mutation in the parathyroid hormone receptor type 1 (PTHR1) gene
(R150C PTHR1) has been found in two patients with Ollier disease, of which in one case the
mutation was also found in the father of the patient. This may suggest a hereditary component
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in Ollier disease. The mutation could not be found in any healthy individuals, nor in 50 cases
of sporadic chondrosarcomas. This single base-pair substitution results in a constitutive active
receptor leading to increasing cAMP signaling, resulting in slowed chondrocyte differentiation
[23]. PTHR1 is part of a negative feedback loop involved in the maturation and differentiation
of cartilage, which includes other proteins such as Indian Hedgehog (IHH) and BCL2. In
high-grade central chondrosarcomas overexpression of PTHLH and BCL2 is seen, suggesting
that the IHH/PTHLH pathway could perhaps indeed be affected (Figure 2.1) [17].
Other genes that have been tested for the presence of mutations in central chondrosarcomas
are p53 and p16. The p53 gene has been found to be genetically affected in some
chondrosarcomas, mainly high-grade. They can show mutations and/or LOH on chromosome
17p13 at the p53 locus [24-28]. The p16 gene, located on chromosome 9p21, has been studied
extensively in central chondrosarcomas. Although both cytogenetics and LOH point to the
9p21 region as an important candidate locus for central chondrosarcoma development [29],
mutations were absent and methylation (a mechanism of gene downregulation) of the p16
gene combined with absent p16 protein expression is found in only a subset of central
chondrosarcomas [30-32].
Secondary peripheral chondrosarcoma
Secondary peripheral chondrosarcomas develop within the cartilaginous cap of a pre-existing
sporadic or hereditary osteochondroma. The hereditary cases represent patients with multiple
exostoses (MO), an autosomal-dominant disease with genetic heterogeneity. These patients
have multiple osteochondromas, deformities of the forearm and disproportionate short statue.
The development of secondary peripheral chondrosarcomas is estimated to occur in < 1% of
solitary osteochondromas and in 1-3% of cases of MO [33,34].
Genetics
Multiple osteochondromas is a genetically heterogeneous disorder and, so far, two genes
have been identified, EXT1 (8q24) and EXT2 (11p11-p12) [35-38]. Additionally, linkage to
MO has been found at chromosomal region 19p [39] but the gene has never been identified
and LOH is absent at this locus [22,40,41]. Most mutations found in patients with MO result
Figure 2.1: Multistep genetic model for central cartilaginous tumorigenesis
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in truncation or a nonfunctional protein, inactivating the gene. In addition, both copies of an
EXT gene need to be inactivated for an osteochondroma to develop in hereditary cases (Figure
2.2) [41,42]. These genes are therefore hypothesized to be tumor-suppressor genes.
For sporadic cases, however, only one somatic mutation in a sporadic osteochondroma has
been described [43,44], although LOH of the EXT genes is found in chondrosarcomas derived
from sporadic osteochondromas.
Peripheral chondrosarcomas developing secondary to osteochondroma demonstrate DNA
aneuploidy with DNA indices ranging from 0.56 to 2.01, equivalent to respective half and
double portions of genetic material. Only mild aneuploidy is found in osteochondromas
[44]. Near haploidy, which is very uncommon for human tumors, is restricted to low-grade
tumors. It is hypothesized that additional genetic hits in the cartilaginous cells of
osteochondroma lead to genetic instability, characterizing malignant progression towards
low-grade secondary peripheral chondrosarcoma, which includes near-haploidy resulting in
the detection of a high percentage of LOH [22]. High-grade peripheral chondrosarcomas
display polyploidization of near haploid precursor clones, as confirmed by LOH and FISH
analysis (Figure 2.2) [22,44]. This extensive LOH may be considered as a hallmark of
peripheral chondrosarcomas, but obscures the detection of specifically targeted loci. Moreover,
cytogenetic analysis did not reveal any specific aberrations in peripheral chondrosarcomas
[29,45].
Proteins
The EXT gene products are involved in the biosynthesis of heparan sulfate [46-48]. Heparan
sulfate is important for the anchorage of the cells to the matrix and is involved in high
affinity binding of growth factors. Mutation of an EXT gene effects heparan sulfate synthesis
and may influence the distribution of IHH, a member of the negative feedback loop that
includes other proteins such as PTHLH (-receptor), fibroblast growth factor (FGF) (-receptor)
and BCL2, and may be involved in the regulation of proliferation and differentiation of
chondrocytes in the normal growth plate [49,50].
These putative downstream targets of EXT, proteins from the IHH/PTHLH (PTHLH, PTHR1,
BCL2) and the FGF pathway (FGF2, FGFR1, FGFR3, p21) were demonstrated to be mostly
Figure 2.2: Multi-step genetic model for peripheral cartilaginous tumorigenesis
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absent in osteochondromas (Figure 2.2). Upregulation of these proteins was seen in peripheral
chondrosarcomas and the expression increased with histological grade. Upregulation of BCL2
and PTHLH was shown to specifically characterize the progression from osteochondroma
towards low-grade secondary peripheral chondrosarcomas (Figure 2.2) [17]. Moreover, BCL2
was recently confirmed as a valuable immunohistochemical marker for the distinction between
osteochondroma and low-grade secondary peripheral chondrosarcoma, in which moderate-
to-strong or diffuse cytoplasmic staining is highly suggestive (95%) of malignancy [51].
Unfortunately, BCL2 expression does not characterize malignant progression of enchondroma
towards low-grade central chondrosarcoma and to date such markers are still lacking.
Prognostic factors in chondrosarcoma
Thus far, the best prognostic parameter in both primary conventional and secondary peripheral
chondrosarcoma is histological grade. Since chondrosarcomas are heterogeneous, adequate
sampling of the tumor is essential [52]. Because histological grading can be difficult on
small samples, many studies have attempted to find molecular markers that can help distinguish
good and poor prognosis in chondrosarcoma. Unfortunately, most literature on potential
prognostic factors does also not distinguish central and peripheral chondrosarcoma subtypes.
Clinical and microscopical prognostic indicators
The best known prognostic indicators for chondrosarcomas are based on clinicopathological
criteria. The major factors are tumor localization and size, histological subtype of
chondrosarcoma and histological grade. Size of the tumors can be an indication of the
likelihood of recurrence [6] and the chance of development of metastases (Table 2.1) [3].
The assessment of tumor subtype is also important since the different subtypes have different
prognosis. For instance, dedifferentiated chondrosarcomas have an ominous prognosis, with
90% of patients dying with distant metastases within 2 years [53]. In contrast, juxtacortical
chondrosarcomas have a very good prognosis, if the tumor has been adequately removed
[54]. Grade is of importance because the risk of metastasis increases with increasing
histological grade [5,7]. Incomplete excision or excision with minor margins results in a
higher chance of recurrence. This recurrence can be of the same or higher grade than the
primary tumor [5,7].
In addition, anatomical location is of importance [19,55], since location in pelvis has a much
worse chance of curative treatment [3,56] than location in the extremities. Moreover,
chondrosarcomas in phalanges have an excellent prognosis since they rarely metastasize,
despite ominous histological features [57]. Extension of the tumor in soft tissues is also a
negative risk factor, since this often leads to local recurrence.
Molecular prognostic indicators
Several attempts have been made to find molecular markers that can indicate the
aggressiveness of the tumor and the chance of local recurrence or metastasis (Table 2.2).
Most of these markers are, however, not independent of tumor grade in a multivariate statistical
analysis and do therefore not have any additional prognostic value.
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Angiogenesis in chondrosarcoma
Important candidates for prognostic markers were thought to be molecules involved in
angiogenesis. Histologically, low-grade chondrosarcomas have a fibrovascular stroma
surrounding the avascular cartilaginous nodules, while in high-grade chondrosarcomas
vascularisation is more prominent including both fibrovascular stroma and vessels in direct
apposition to tumor cells [15].
Angiogenesis, as seen in high-grade chondrosarcomas, requires invasion by endothelial cells.
It has been suggested that vascular endothelial growth factor - whose expression appears to
be restricted to tumor cells of high-grade chondrosarcomas (Table 2.2) - is required for vessels
to penetrate the cartilage [15]. Moreover, localized proteolytic modification of the extracellular
matrix is required, for instance by matrix metalloproteinases (MMP). The activity of MMPs
is related to invasiveness and metastatic potential of tumors. It is suggested that increased
expression of MMP-1, -2, -9 and -13 and a decrease in MMP-3 and -8 expression may be
associated with a high-grade malignant phenotype in cartilaginous tumors (Table 2.2)[58-
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64]. Proteolytic activity is, however, determined by the overall balance between the activity
of MMPs and the activity of tissue inhibitors of MMPs (TIMPs). TIMP-1 and -2 expression
has also been demonstrated in chondrosarcoma [58,62,65-67] and a high ratio of MMP-1 to
TIMP-1 is associated with poor outcome (Table 2.2)[58,65].
Other molecular prognostic factors
In addition, several other factors have been tested, like heat shock protein 72 [68], FGFs
[17], plasminogen activators (PA) [55,64,69] and cathepsins (Table 2.2) [64,64,67]. For
instance, cathepsin B is an enzyme involved in lysosomal proteolysis and degradation of
antigens correlating with poor prognosis when overexpressed (Table 2.2) [64]. However, it
is difficult to define cathepsin B overexpression.
Genetic prognostic indicators
A recently reported prognostic factor is loss of chromosomal region 13q. Investigation of 59
chondrosarcomas showed it to be an independent prognostic factor for metastasis (relative
risk = 5.2), regardless of tumor grade or size [67]. In this study, other genomic aberrations
such as 6q, 10p, 11p, 11q, 22q also showed a correlation with impaired metastasis-free survival.
However, significance was lost in a multivariate statistical analysis when other factors, like
tumor grade and size, were included in the comparison [70].
DNA flow cytometry data do also have some prognostic value [71-79]. The tumours showing
aneuploidy are mainly high-grade chondrosarcomas and thus have a worse prognosis (Table
2.2). Therefore, aneuploidy is not a prognostic factor independent of histological grade.
The complex and aspecific cytogenetic aberrations that increase with histological grade
interfere with the identification of specific prognostic factors. The result is that different
lesions show different karyotypes and/or mutations with some found more often than others.
A good example is p53 which has been found mutated in a subset of the chondrosarcomas,
mainly related to high-grade or dedifferentiated chondrosarcomas, but not in all (Table 2.2)
[24,25,27,28,68,72,80,81].
Summary and conclusions
Although the mechanisms of chondrosarcoma development have been the subject of many
studies in the past, their multistep genetic pathways are just beginning to unravel. Based
upon their location, the tumors can be subdivided in two groups: central and peripheral,
which demonstrate different mechanisms of development. Most of the multistep genetic
model for central chondrosarcoma development remains to be elucidated. In contrast, more
is known about the multistep model for secondary peripheral chondrosarcomas, arising in
the cartilaginous cap of osteochondroma. For development of osteochondromas both copies
of the EXT genes need inactivation. In addition, secondary peripheral chondrosarcomas
demonstrate genetic instability, including near-haploidy. High-grade peripheral
chondrosarcomas show polyploidization of these near-haploid precursor clones. Thus far,
the distinction between benign and low-grade malignant cartilaginous tumors has been difficult
and is mainly based on radiological and clinico-pathological features. It would be helpful to
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have molecular markers to aid the pathologist in this differential diagnosis. BCL2 is a good
diagnostic marker that can be used in the distinction between osteochondroma and low-
grade secondary peripheral chondrosarcoma. Thus far, no diagnostic markers have been
identified for central tumors. For the prognosis of chondrosarcomas the best available marker
is the histological grade. Many molecular and genetic markers were tested on chondrosarcomas
but most are not independent of histological grade and therefore do not have additional
prognostic value, except in small lesions not big enough to ascertain the histological grade
by using the present criteria.
Expert opinion
The difference between benign and low-grade malignant cartilaginous tumors is difficult
and is so far mainly based on clinico-pathological and radiological features. Unfortunately,
most of the research on chondrosarcomas does not distinguish between central and secondary
peripheral chondrosarcomas, probably because of their similar cytonuclear features. Although
peripheral chondrosarcomas are rare, the distinction is, however, important because they
have a different genetic etiology. Thus, it is imperative to distinguish between central and
secondary peripheral chondrosarcomas, since it is likely that diagnostic and prognostic markers
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may also be different for the two subtypes, as is demonstrated by BCL2 being a diagnostic
marker for peripheral but not for central tumors. Eventually, a similar pathway may turn out
to be affected at different levels, for which the EXT downstream negative feedback loop,
involved in the formation and maturation of chondrocytes within the normal growth plate, is
a good candidate.
Five year view
In the next 5 years, more molecular and genetic markers will probably be tested. Many of
these markers will be chosen hypothetically, based on their involvement in what is presently
known about the development and maturation of chondrocytes in physiological circumstances.
In addition, other pathways involved in the development of chondrosarcomas and their benign
lesions may be discovered with the use of new high-throughput techniques such as cDNA
microarray. This will probably lead to an improved understanding of the biology of
chondrosarcomas, which may in turn lead to better diagnostic and prognostic markers.
Key issues
· The distinction between benign and low-grade malignant chondrosarcomas can be diffi-
cult and is currently based on radiologic and clinicopathologic features
· Conventional chondrosarcomas are classified in three histological grades, correlating with
prognosis
· Based on their location in bone, conventional chondrosarcomas should be subdivided into
central (medullary cavity) and peripheral (surface of bone, within osteochondroma) chon-
drosarcomas
· Peripheral and central chondrosarcomas have a different genetic mechanism
· BCL2 is a good diagnostic tool for the identification of progression from osteochondro-
mas to low-grade secondary peripheral chondrosarcomas
· A diagnostic tool to distinguish enchondromas from low grade central chondrosarcomas is
still lacking
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Chapter 3
Molecular analysis of the INK4A / INK4A-ARF gene locus in conventional (central)
chondrosarcomas and enchondromas: Indication of an important gene for tumor
progression
HM van Beerendonk, LB Rozeman, AHM Taminiau, R Sciot, JVMG Bovée, AM Cleton-
Jansen, PCW Hogendoorn
Journal of Pathology. 2004; 202 (3): 359-66
Loss of heterozygosity (LOH) at chromosomal band 9p21 is one of the few consistent genetic
aberrations found in conventional central chondrosarcoma. This locus harbors two cell cycle
regulators CDKN2A/p16/INK4A and INK4A-p14ARF, which are inactivated in various human
malignancies. It was therefore hypothesized also plays a role in the development of
chondrosarcomas and this locus was investigated at protein, genetic, and epigenetic levels.
Loss of p16 protein expression was detected by immunohistochemistry in 12 of 73 central
chondrosarcomas and it correlated with increasing histological grade (p = 0.001). Loss of
p16 protein expression was not found in 51 enchondromas, which are presumed to be potential
precursors of conventional central chondrosarcoma. LOH at 9p21 was found in 15 out of 39
chondrosarcomas (38%) but it did not correlate with loss of p16 protein expression. SSCP
analysis of p16 did not reveal any mutations in 47 cases. Also, p14 was not the target of
LOH, since it gave no aberrant bands in SSCP. To investigate whether an epigenetic mechanism
was operating, methylation-specific PCR was used to look at promotor methylation of
CDKN2A/p16, which was identified in 5 of 30 tumors. However, this did not correlate with
protein expression, or with LOH at 9p21. Cytogenetic data were available in a subset of
cases. All tumors that showed chromosome 9 alterations also showed LOH and loss of INK4A/
p16 protein expression. It is concluded that although some alterations were found at the
DNA level and at the promoter expression level, the lack of correlation between LOH,
promotor methylation and protein expression indicates that a locus other than the CDKN2A/
p16 must be the target of LOH at 9p21. The correlation between INK4A/p16 protein expression
and tumor grade and the retention of expression in enchondromas, indicates that loss of
INK4A/p16 protein expression may be an important event during tumor progression from
enchondroma to conventional central chondrosarcoma, and in the progression in grade after
recurrence of chondrosarcoma.
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Chondrosarcomas are malignant cartilage-forming bone tumors, with an occurrence of about
1 in 100.000 in the general population [1,2]. There are three grades of malignancy that correlate
with prognosis [3]. Based upon their location in the bone, there are two major subtypes of
conventional chondrosarcomas. The majority of the tumors are localized in the medullary
cavity of long bones, so-called conventional central chondrosarcomas. Enchondroma may
be its benign precursor in rare cases. Malignant transformation of enchondroma is, however,
a rare event, especially in enchondroma of the phalanx, a site where chondrosarcomas are
extremely rare, despite the fact that hands and feet harbor 35% of enchondromas [4]. A
hereditary form of conventional central chondrosarcomas is not known. Enchondromas arising
in the context of Ollier disease and Maffucci syndrome, two non-hereditary conditions
displaying multiple enchondromas, have a much higher risk to become malignant, i.e. 30-
35% (OMIM #166000) [5]. A minority of chondrosarcomas arise secondary to a pre-existing
osteochondroma, and are called secondary peripheral chondrosarcomas [1,2,6]. We have
shown that secondary peripheral chondrosarcomas are characterized by gross chromosomal
instability reflected by a high percentage of LOH with almost all chromosomes involved,
and a broad ploidy range [7-9]. In contrast, genetic aberrations in conventional central
chondrosarcomas are sparse and the tumors are often (peri)diploid. This suggests that only
limited genetic alterations are sufficient for tumorigenesis in conventional central
chondrosarcomas. Previously, we demonstrated LOH at 9p21 in 3 of 12 (25%) conventional
central chondrosarcomas. Moreover, a cytogenetic study of 7 of 16 conventional central
chondrosarcomas showed cytogenetic aberrations, of which five involved chromosome 9p12-
22 [7]. These data suggest that the 9p21 region may be important in its tumorigenesis. At
chromosome 9p an important region is the INK4A/ARF locus (9p21), encoding the proteins
INK4A/p16 and INK4A/p14ARF. The activation of INK4A/p16 and INK4A/p14ARF results
in blockage of cell-cycle progression and inhibition of cellular proliferation. Mutational or
transcriptional inactivation of the CDKN2A/p16 and p14 genes can lead to uncontrolled
growth. CDKN2A/p16 is inactivated in several tumor types, including bone sarcomas [10-
13], either by homozygous deletion, mutation or extensive de novo methylation-inhibiting
gene transcription [14]. To investigate if this locus is the target of the LOH at chromosome
9p in conventional central chondrosarcomas, we present the results of immunohistochemistry,
LOH analysis, SSCP analysis (INK4A/p16 and INK4A/ARF), and promoter methylation
status of the INK4A locus on a large well-characterized patient series.
MATERIALS AND METHODS
Patient material
All tissue samples were handled in a coded fashion. The specimen codes indicated patient
data were only available via physicians involved in the diagnosis and treatment of these
patients. All procedures were performed according to local ethical guidelines. Table 3.1
shows the clinico-pathological data of the patients in this study. In total, 73 tumor specimens
from patients treated between 1986 and 2001 with a histological diagnosis of conventional
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central chondrosarcoma were retrieved from our files. Peripheral, dedifferentiated,
mesenchymal, juxtacortical and clear-cell chondrosarcomas were excluded. Conventional
central and secondary peripheral chondrosarcomas were distinguished on the basis of accepted
clinico-pathological and radiological criteria [1]. Histological grading was performed
according to Evans et al [3].
In addition, tumor material from 51 enchondromas was included: 14 enchondromas of the
phalanx and 37 enchondromas from other locations of the long bones. According to the 2002
WHO definition, all enchondromas were located centrally in the bone, as documented by X-
ray. Phalangeal and non-phalangeal localization were analyzed separately. An expert bone-
tumor pathologist reviewed all cases to confirm the diagnosis. Formalin-fixed paraffin wax-
embedded tissue was available from all patients; for a subset of chondrosarcomas (n=47),
fresh frozen tissue was also available. Follow-up data were retrieved from clinical charts and
from files of The Netherlands Committee on Bone Tumors.
Immunohistochemistry
Immunohistochemical staining was performed with the monoclonal INK4A/MTS1 antibody
(Neomarkers, Fremont, CA, USA) according to standard laboratory methods [15]. In short,
antigen retrieval was performed using 0.01 M Citrate solution. Sections of tonsil were used
as a positive control.
The staining intensity (0 = negative, 1 = weak, 2 = moderate and 3 = strong intensity) and the
percentage of positive cells (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 = 50-74%, 4 = 75-100%)
were evaluated by two observers independently [8]. In of discrepant cases, the sections were
re-analyzed to obtain consensus. Haematopoietic cells in bone marrow or endothelial cells
served as an internal positive control to evaluate whether negative tumor cells are truly
negative or whether prolonged decalcification might have altered the conformation of the
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antigen, resulting in a false-negative result. INK4A/p16-negative tumors without a positive
internal control were excluded.
Loss of heterozygosity and CDKN2A/p16 and p14ARF SSCP analysis
DNA-isolation
Paraffin wax-embedded cartilaginous tissue is not suitable for DNA analysis because the
decalcification process with formic acid results in DNA degradation. From 40 patients with
chondrosarcomas, DNA from fresh-frozen tissue and matched normal DNA were available.
Only tumor tissue was available from seven patients. Normal DNA was prepared from
peripheral blood drawn from patients after informed consent, or from normal muscle or skin
obtained from resected specimens. Tumors with tumor cell percentages over 60% were
included for genetic analysis [8]. No frozen material was available from enchondromas.
DNA isolation from frozen sections was performed using proteinase K treatment and
subsequent purification with the Wizard Genomic DNA Purification Kit (Promega, Madison,
WI, USA) according to the manufacturer’s instruction. DNA from blood samples was isolated
using a salting- out procedure [16].
Loss of heterozygosity analysis
No matching normal DNA was available from seven samples and therefore those seven
samples were not suitable for LOH analysis, leaving 40 tumors. For the study of LOH on
chromosome 9p, the following polymorphic microsatellite markers were used: D9S269,
D9S274, D9S319 and D9S304 (http://gdbwww.gdb.org). The location of the markers in
relation to CDKN2A/p16/INK4A is shown in Figure 3.1.
LOH analysis and scoring have been described previously [17]. LOH results had to be
reproducible in a consecutive analysis.
CDKN2A SSCP analysis
Genomic DNA from 47 tumors was used for SSCP analysis. Both genes encoded by the
CDKN2A locus, p16 and the p14/ARF, were investigated. The CDKN2A/p16 gene was
screened as described previously and covers the entire open reading frame [18]. Additional
primers were designed for the P14/ARF exon 1β. The exon 1β was divided into two
Figure 3.1: Schematic representation of the CDKN2A/p16 and p14ARF genes, flanked by the markers on chromo-
some 9p21 that were used for LOH-analysis
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overlapping fragments. Primers for the two fragments of exon 1β are: F1: 5'-
CACCTCTGGTGCCAAAGG-3' and R1: 5'-GCCTCCTCAGTAGCATCAGC-3' (A fragment
219 bp) and F2: 5'-GCCGCGAGTGAGGGTTTT-3’and R2:5'-CACCGCGGTTATCTCCTC-
3' (B fragment 257 bp).
Methylation-Specific PCR (MSP) analysis
Promoter methylation was determined according to Herman et al [19], based on bisulphite
modification and subsequent PCR specific for methylated versus unmethylated CDKN2A/
p16 promoter sequence.
One microgram of genomic DNA from 30 fresh-frozen tumors was used for MSP analysis
and modified using the CpGenome DNA Modification Kit (Intergen, New York, USA).
Subsequent CDKN2A/p16-promoter methylation status was analyzed using the CpG WIZ
Amplification Kit (Intergen). After amplification, samples, methylated, unmethylated, and
wildtype controls were analyzed on a 2% agarose gel.
Statistical analysis
The SPSS package was used for all statistical analyses. Histological parameters were analyzed
using the chi-square test for trend. Kaplan-Meier curves and the log-rank test were used to
study the effect of INK4A/p16 protein expression and LOH on disease free survival.
RESULTS
Immunohistochemistry
In total, 14 of 69 (20 %) chondrosarcomas demonstrated complete loss of INK4A/p16 protein
expression (Figure 3.2c), which was restricted to higher-grade lesions: 0 (0%) of 24 grade I
chondrosarcomas demonstrated loss of expression, compared to 9 (27%) of 33 grade II and
5 (42 %) of 12 grade III chondrosarcomas (p = 0.001, chi-square test for trend). In contrast,
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none of the enchondroma cases showed loss of INK4A/p16 expression. One of eight patients
with Ollier’s disease demonstrated loss of INK4A/p16 protein expression in a grade II
conventional central chondrosarcoma. The results of the immunohistochemical analysis of
INK4A/p16 stainings are shown in Table 3.2. Immunohistochemical INK4A/p16 staining
can result in positive nuclear or cytoplasmic staining. In the tumors tested we found both
nuclear and cytoplasmic staining (Figure 3.2a). Five of 73 samples showed only cytoplasmic
staining. There were also some cases showing focal positive INK4A/p16 staining as shown
in Figure 3.2b. Four specimens could not be evaluated due to repeated loss of tissue attachment
during microwave procedures.
Loss of heterozygosity and CDKN2A SSCP analysis
SSCP
To investigate if CDKN2A/p16 and p14/ARF are inactivated by a genetic mutation, we carried
out SSCP analysis on the four exons encoding these genes and performed LOH analysis with
polymorphic microsatellite markers adjacent to the CDKN2A locus. SSCP was chosen as
Figure 3.2: Light micrograph showing the immunohistochemical nuclear and cytoplasmic localization of INK4A/
p16. (A) Positive staining of INK4A/p16 in a grade II conventional central chondrosarcoma. (B) Some conven-
tional central chondrosarcomas showed focal positive INK4A/p16 staining. (C) Fifteen per cent of the conven-
tional central chondrosarcomas were entirely negative for INK4A/p16 staining; the inset shows the internal posi-
tive control of the tumour (endothelial cells). Color picture can be viewed at page 127
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the technique to determine mutations because the method has proven useful for the
identification of INK4A mutations previously in melanoma [18] and because it is able to
detect up to 90% of mutations in a background of non-tumor tissue, which is not possible by
sequencing. In two samples from melanoma patients with previously confirmed CDKN2A/
p16 mutation in exon 2 from CDKN2A/p16 an aberrant SSCP pattern could be detected,
validating the SSCP analysis. None of the 47 chondrosarcomas revealed aberrant bands at
the CDKN2A/p16 and p14/ARF loci. Figure 3.3 shows an example of an SSCP analysis on 5
chondrosarcomas and a melanoma with a known mutation in CDKN2A/p16.
LOH
As shown in Table 3.3, LOH at 9p21 for one or more markers was found in 15 of 40 (37.5%)
cases. LOH was mainly found in grade II and III tumors. LOH for one or more markers in the
9p21 region was found in 2 of 10 (22%) grade I, 11 of 21 (52%) grade II and 4 of 6 (67%)
grade III chondrosarcomas (p = 0.054, chi square test for trend).
For 12 cases, all informative markers at 9p showed LOH. There was also one tumor that
showed loss of one marker and retention of an adjacent one, but the region involving LOH
included the INK4A locus in all cases.
Figure 3.3: Example of SSCP analysis of CDKN2A/p16 exon 2, c-fragment. Lanes 1-5 represent PCR products
from five different conventional central chondrosarcoma samples and + is a melanoma sample containing a known
mutation in exon 2. An arrow indicates the band shift in the positive control
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Remarkably, for all three patients with Ollier disease, LOH for one or more markers in the
9p21 region was found.
As shown in Table 3.3, there is no clear correlation between LOH at 9p and the loss of
protein expression.
Promoter Methylation
Table 3.4 shows the results of the promoter methylation analysis by MSP. An example of
MSP is shown in Figure 3.4. DNA was available to study promoter methylation from six of
ten patients with absent INK4A/p16 protein expression. Twenty-four additional patients were
selected with varying INK4A/p16 staining intensities with INK4A/MTS1 antibody.
Methylation of the CDKN2A/p16 promoter was detected in 5 of 30 (13%) cases. Detectable
promoter methylation was not clearly associated with loss of INK4A/p16 protein expression
(Table 3.4).
Figure 3.4: Example of MSP analysis. All DNAs were modified with bisulphite. The samples in lanes 1-4 are
amplified with primers for the methylated state and those in lanes 5-8 samples amplified with primers for the
unmethylated state. Lanes 1 and 5 are of a conventional central chondrosarcoma; lanes 2 and 6 are unmethylated
control DNAs; lanes 3 and 7 are methylated control DNAs; and lanes 4 and 8 are samples amplified without DNA
to serve as a negative control. Lane M is a 100 bp ladder
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Statistical analysis
There is a significant relation between loss of INK4A/p16 protein expression and increasing
tumor grade (p = 0.004, chi-square test for trend). Both LOH for one or more markers in the
9p21 region and complete loss of INK4A/p16 expression also seemed to correlate with a
poor prognosis; this was, however, not statistically significant (p=0.0828 and p=0.1271,
respectively, log-rank test) and was not independent of histological grade, which was a strong
prognostic parameter (p = 0.000, log-rank test).
Ten of 27 chondrosarcomas that showed INK4A/p16 expression showed also LOH. The
staining intensity and the percentage of cells demonstrating INK4A/p16 expression seemed
slightly lower in INK4A/p16 positive tumors with LOH than in INK4A/p16 positive tumors
without LOH although the difference was not statistically significant (mean score for intensity
1.38 versus 1.74, mean score for percentage of positive cells 1.54 versus 2.05, mean total
score 2.92 versus 3.79).
DISCUSSION
Few genetic aberrations have been identified in conventional central chondrosarcomas,
suggesting that limited genetic alterations are required for tumorigenesis. LOH and other
cytogenetic alterations at 9p21 are, however, repeatedly found, suggesting an important role
in tumorigenesis for genes located in this region. The CDKN2A/p16 locus at 9p21 is an
excellent candidate, since it was shown to be inactivated in multiple tumor types including
bone sarcomas [14]. The CDKN2A/p16 gene has been investigated previously in
chondrosarcoma, but a heterogeneous group of chondrosarcomas was used and only one
genetic alteration was found [20]. These authors identified promoter methylation in 5 of 22
cases, but loss of expression was not confirmed by immunohistochemistry.
Here we present a carefully selected group of conventional central chondrosarcomas only,
stratified according to differentiation, grade and etiology, and their potential precursors,
namely enchondromas. A study for CDKN2A/p16 was performed on the level of protein,
genetic alterations, promoter methylation, and mutational analysis of p14/ARF. Furthermore,
we investigated whether INK4A/p16 protein expression level can be used as a predictive
marker for tumor progression in conventional central chondrosarcomas.
Two separate subgroups were discerned within our tumors:
1. Tumors located in the phalanx versus those located elsewhere, since phalangeal chondrosa-
rcomas are extremely rare and have a far better prognosis compared to chondrosarcomas
located elsewhere [4]. Both enchondromas of the phalanx as well as enchondromas lo-
cated elsewhere failed to demonstrate loss of INK4A/p16 protein expression.
2. Conventional central chondrosarcomas that occur in the context of Ollier disease [5,21]
versus sporadic cases. Chondrosarcomas in the context of Ollier disease may have a worse
prognosis than normal chondrosarcomas [22,23]. Four chondrosarcomas of Ollier disease
patients were available for this study and one showed loss of INK4A/p16 protein expres-
sion. Remarkably, however, all three patients with Ollier disease used for the LOH analy-
sis demonstrated LOH for one or more markers in the 9p21 region. This is consistent with
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previous data [24] and suggests that INK4A/p16 is not more often involved in Ollier dis-
ease than in solitary chondrosarcomas. Rather, another gene located in the 9p21 region
may be important in chondrosarcoma in Ollier disease.
This study shows that conventional central chondrosarcomas demonstrate loss of INK4A/
p16 expression by immunohistochemistry in 20% of cases tested and this loss increases with
histological grade. Enchondromas show no loss of INK4A/p16 expression. This is concordant
with the low proliferative activity in enchondromas and the role of INK4A/p16 in inhibition
of cell cycle progression. In dysplastic nevi, LOH, mutations, and loss of protein expression
of INK4A/p16 have been reported but only in a small fraction, whereas melanomas often
show INK4A/p16 alterations, suggesting a role for this gene in tumor progression in this
situation too [25-28] . Five tumors showed only cytoplasmic and no nuclear staining. It is
previously described that breast tumors with only cytoplasmic INK4A/p16 staining have a
more aggressive behavior [29], but this cannot be concluded for chondrosarcomas, because
the tumors that showed only cytoplasmic staining were low grade.
In many other tumors, especially melanoma, the CDKN2A/p16 locus is the target for LOH at
9p21 [18,30,31]. Our LOH analysis shows that CDKN2A/p16 is included in the region in all
cases with LOH of at least one marker at 9p21. LOH at 9p21 was relatively frequent (37%)
and comparable with previous results [8,32,33].
LOH at 9p increased with histological grade, which is most probably a reflection of overall
increase of genetic instability in higher-grade tumors [34]. Whether CDKN2A/p16 is the
target of LOH at chromosome 9p21 could not be assessed because SSCP analysis did not
identify mutational inactivation of the retained copy of CDKN2A/p16 and p14/ARF in any of
the tumors tested. Furthermore, there was no association between LOH at 9p21 and
immunohistochemical loss of INK4A/p16 protein expression. The 9p12-22 region was
involved in five of seven conventional central chondrosarcomas with an aberrant karyotype
[7]. Two of the five cases demonstrating –9, t(9;10)(p22;q22) and add(9)(p21) could be
included in the present analysis and both showed loss of INK4A/p16 protein expression and
LOH at 9p21.
Homozygous deletions of the CDKN2A region have been described occasionally in cell lines
and primary tumors of different origin [35,36]. We cannot exclude that such deletions have
been missed in our study. However, because there is no obvious relation between LOH and
INK4A/p16 protein expression in our study, homozygous deletions of CDKN2A/p16 in
conventional central chondrosarcomas are unlikely.
Another mechanism for tumor suppressor gene inactivation is epigenetic promoter
methylation, which has been described for the CDKN2A/p16 gene [37]. Indeed, we found
methylation in 5 of 30 patients. However, there was no association between LOH at 9p21
and methylation, since only two of these cases showed LOH. There was no significant relation
between protein expression and CDKN2A/p16 promoter methylation, since we identified
four tumors that have promoter methylation without loss of INK4A/p16 protein expression.
With increasing age, methylation of several target genes can be detected in normal tissue
[38-40]. The average age of the patients that showed CDKN2A/p16 promoter methylation
was 41.4 years. This is even less than the average age of all patients with conventional
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central chondrosarcomas, namely 50.8 years, thereby indicating that age-dependent promoter
methylation is not likely. An alternative explanation for the discordance between CDKN2A/
p16 promoter methylation and protein expression is the focal INK4A/p16 positive stained
areas next to areas with no INK4A/p16 expression (Figure 2b), indicating tumor heterogeneity
with regard to INK4A/p16 promoter methylation. Interestingly, we did not find promoter
methylation in low-grade chondrosarcomas.
CDKN2A/p16 alterations have also been identified in other bone sarcomas as well, such as
osteosarcomas [10,11], Ewing sarcomas [10,12] and malignant fibrous histiocytomas of bone
(MFH-b) [13]. About 30% of Ewing sarcoma and osteosarcoma show abnormalities
(mutations, deletions, and promoter methylation) of the INK4A locus. For MFH-b only 1 of
19 tumors showed a CDKN2A/p16 mutation. Ewing sarcomas show a negative correlation
between mutations and deletions of the INK4A locus and prognosis.
In conclusion, loss of INK4A/p16 protein expression occurs in one-third of conventional
central chondrosarcomas by an as yet unknown mechanism and is associated with higher
tumor grade. Although we find LOH at 9p21 in 38% of cases, there was no association
between LOH and loss of INK4A/p16 protein expression. Thus, neither the CDKN2A/p16
nor p14/ARF locus appears to be the target and therefore another gene is most likely involved
by this recurrent genetic aberration. Also, CDKN2A/p16 promoter methylation does not
explain this phenomenon, because we did not find an association with loss of protein
expression. It is of importance that CDKN2A/p16 loss is more frequent in high-grade tumors
and is absent in enchondroma. It has been reported that recurrences of chondrosarcoma
sometimes demonstrate an increase in the degree of malignancy [1,2]. This suggests that
loss of INK4A/p16 protein expression is an important event during tumor progression in
enchondroma, as well as the progression in grade in recurrent chondrosarcoma.
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Chapter 4
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1
mutation p.R150C
LB Rozeman, L Sangiorgi, IH Briaire-de Bruijn, P Mainil-Varlet, F Bertoni, AM Cleton-
Jansen, PCW Hogendoorn, JVMG Bovée
Human Mutation. 2004; 24: 466-473
Enchondromatosis (Ollier disease, Maffucci syndrome) is a rare developmental disorder
characterized by multiple enchondromas. Not much is known about the molecular genetic
background. Recently an activating mutation in the parathyroid hormone receptor type 1
(PTHR1) gene, c.448C>T (p.R150C), was reported in two of six patients with
enchondromatosis. The mutation is thought to result in upregulation of the IHH/PTHLH
pathway. This is in contrast to previous studies, showing downregulation of this pathway in
other cartilaginous tumors. Therefore, we investigated PTHR1 in enchondromas and
chondrosarcomas from 31 enchondromatosis patients from three different European countries,
thereby excluding a population bias. PTHR1 protein expression was studied using
immunohistochemistry, revealing normal expression. The presence of the described PTHR1
mutation was analyzed, using allele specific oligonucleotide oligonucleotide hybridization
confirmed by sequence analysis, in tumors from 26 patients. In addition, 11 patients were
screened for other mutations in the PTHR1 gene by sequence analysis. Using both allele-
specific oligonucleotide hybridization and sequencing we could neither confirm the previously
found mutation nor find any other mutations in the PTHR1 gene. These results indicate that
the PTHR1 gene is not, in contrast to previous suggestions, the culprit for enchondromatosis.
46
Chapter 4
Ollier disease (enchondromatosis, MIM #166000) is a rare developmental disorder that seems
to distribute in a non-hereditary manner. The syndrome is characterized by skeletal deformities
and multiple enchondromas, often with unilateral predominance [1]. Enchondromas are benign
cartilaginous lesions, located in the metaphyseal medulla of bone. The solitary form of
enchondroma is far more common than the rare occurrence within the context of
enchondromatosis.
Maffucci syndrome is a rare variant of enchondromatosis characterized by both multiple
enchondromas and benign hemangiomas [2]. Apart from these two enchondromatosis
syndromes, recognized by the World Health Organization (WHO) [3], there are other
extremely rare distinct variants described, such as spondyloenchondromatosis (MIM
#271550) [4-7].
Malignant transformation of enchondromas to chondrosarcomas occurs in <1% of solitary
cases [8], and 25 to 30% of enchondromatosis cases [8,9]. Chondrosarcomas can be either
conventional central (83%) or secondary peripheral (17%), with central chondrosarcomas
arising de novo, or as a result of malignant transformation of an enchondroma [10].
Secondary peripheral chondrosarcomas arise, by its definition, secondarily within the
cartilaginous cap of its benign precursor, osteochondroma, which is solitary or occurs in the
context of Multiple Osteochondromas (MO) [11]. In contrast to enchondromatosis, MO
demonstrates a clear autosomal dominant inheritance pattern, caused by EXT1 or EXT2
mutations. EXT mutations are postulated to disturb, via heparan sulphate proteoglycans, the
Indian hedgehog (IHH)/parathyroid hormone like hormone (PTHLH) negative feedback loop
within the normal human growth plate [11,12], and absence of these signaling molecules has
been demonstrated in osteochondromas [13].
Three genetic studies have been reported on enchondromatosis. Cytogenetic analysis showed
a interstitial deletion at chromosomal region 1p in one case [14], loss of heterozygosity
(LOH) at 13q14 and 9p21 and p53 overexpression in chondrosarcoma in another case [15],
and recently, Hopyan et al.[16] described a mutation in the parathyroid hormone receptor 1
(PTHR1, MIM #168468), PTHR1 c.448C>T (p.R150C PTHR1), which was found in two of
six patients with Ollier disease, one a germline and the other probably a somatic mutation.
This mutation was absent in 50 solitary chondrosarcomas and 100 unaffected individuals
[16]. The single nucleotide change in PTHR1 codes for an amino acid change, which results
in a constitutively active receptor, with reduced translocation to the membrane (as shown by
western blot), reduced PTHLH binding (by cell transfection) and a decrease in chondrocyte
differentiation (PTHR1 p.R150C mouse model). The authors argued that, by upregulation of
the IHH/PTHLH signaling, this leads to the formation of enchondromas [16].
It is difficult to perceive that upregulation of IHH/PTHLH signaling would lead to
enchondroma formation, knowing that downregulation of the IHH/PTHLH signaling, as a
result of EXT mutation [11-13,17], plays a role in osteochondroma formation. We therefore
investigated the role of PTHR1 in enchondromatosis, by studying the expression of the PTHR1
protein and screening for the specified p.R150C PTHR1 mutation. In addition, in 11 patients
all exons of the PTHR1 gene were screened for mutations.
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MATERIAL AND METHODS
Patient data
In total, 23 enchondromas and 18 chondrosarcomas from 31 patients with enchondromatosis
were obtained. The samples were collected from the files of The Netherlands Committee for
Bone tumors (three patients, six samples), the Leiden University Medical Center (nine patients,
14 samples), Rizzoli Orthopedic Institute, Bologna, Italy (15 patients, 15 samples) and Institute
of Pathology, University of Bern, Switzerland (four patients, six samples).
Patient data were obtained by review of clinical charts and radiographs. Grading was
performed according to Evans et al.[18]. Patients were included if at least two different sites
were affected by enchondromas and or chondrosarcomas [3]. For patient descriptions, see
Table 4.1. All procedures were performed according to the local ethical guidelines.
PTHR1 immunohistochemistry
Of 24 of the 31 patients paraffin blocks were available for immunohistochemistry. From
each patient one tumor was used. Sections (4 µm) were stained with the polyclonal PTHR1
antibody from Babco (Eurogentec, San Diego, CA) in a 1 in 75 dilution, using a citrate
antigen retrieval as previously described [19]. As a positive control skin was used and vessel
walls and osteoblasts served as an internal positive control. Two independent observers scored
the sections.
DNA isolation
Tumor DNA was isolated from paraffin-embedded (n = 24), as well as fresh frozen material
(n = 12). From 13 patients normal DNA was also obtained (10 from paraffin, two from
frozen tissue and one from blood). The tumor percentage as determined by hematoxylin and
eosin stained slides was at least 70%. DNA from paraffin-embedded material was isolated as
described earlier [20]. Some samples were microdissected to enrich for tumor percentage or
to obtain normal DNA. Samples isolated from paraffin-embedded material with a low DNA
concentration were concentrated using the DNA Clean and Concentrator kit (Zymo research,
Orange, CA). DNA from fresh frozen material was isolated using a wizard genomic DNA
purification kit (Promega, Madison, WI), and DNA of blood was isolated using a salting out
procedure according to Miller and Polesky [21].
R150C PTHR1 PCR
Genomic DNA of the PTHR1 gene (NM_000316.2) containing the position of the p.R150C
PTHR1 mutation was amplified using the PCR primers 5'-TGACACACTCGCTGTAGTTGG-
3' (PTHR1-F) and 5'-TTGGAGCTAGGGGTTCAGTG-3' (PTHR1-R) generating a 154 bp
product. As a positive control, DNA isolated from a normal placenta was used; both to serve
as a control for the PCR and as a wild type control for the allele specific oligonucleotide
oligonucleotide hybridization.
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Construction of the mutant sequence
A plasmid containing the PTHR1 fragment with the c to t substitution (c.448C>T) was
constructed using mutation specific PCR [22]. Detailed description of the construction can
be obtained on request.
ASO hybridization
For detection of the p.R150C PTHR1 mutation PCR fragments of tumor and control DNA
were electrophoresed on a 2% agarose gel and blotted to nylon membranes (Hybond™-N+,
Amersham bioscience, Piscataway, NJ) as described earlier [23]. A separate blot was made
with a dilution series of a mix of wild-type and constructed mutant PCR products in different
concentrations. The blots were hybridized with α-32P oligonucleotides specific for wild type
(5'-ACGCTGTGACCGCAATGGCA-3') or mutant (5'-ACGCTGTGACTGCAATGGCA-3').
Oligonucleotides were labeled in 6 ml containing 20 pmol oligo, 1ml [α-32P] ATP (10 µCi),
1x kinase buffer (70 mM Tris, pH 7.6; 10 mM MgCl2), 9 units T4 PNK kinase (USB; US
Biochemicals, Cleveland, OH) for 1 hour at 37°C and 5 min at 65°C. The blot was hybridized
overnight with a hybridization mix containing 0.5M NaHPO4/NaH2PO4 (pH 7.0), 7% SDS at
65°C (wild-type) and 68°C (mutant). After washing the filters with 1 x SSC/0.5 % SDS, they
were exposed to a Phosphor Imager screen (Amersham bioscience).
The blot containing the samples was first hybridized with the mutant probe, then stripped at
68°C with 0.1 x SSC/0.5% SDS and subsequently hybridized with wild-type probe. Complete
stripping of the blot was checked by phosphor imaging.
Signal intensities were scored as peak heights as detected by ImageQuant (Molecular
Dynamics, Sunnyvale, CA).
Sequencing for the p.R150C PTHR1 mutation
For 19 cases the absence of the mutation, as detected by ASO hybridization, was confirmed
by sequence analysis of the PCR fragment, using the forward and/or reverse PCR primer.
Among the samples chosen were those tumor samples with a relative signal comparable and
lower to the wild type sample. The PCR products of these samples were purified using
QIAGEN QIAquick PCR Purification Kit (QIAGEN, Germantown, MD) prior to sequencing.
Sequencing was performed using the ABI PRISM® Big Dye Terminators v. 2.0 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA). Samples were run on an ABI 3700
Genetic Analyzer (Applied Biosystems).
Sequencing of the entire PTHR1 gene
Fresh frozen tissue to obtain high molecular weight DNA was available for 11 patients affected
by Ollier disease, five of which where not analyzed by the ASO hybridization. Genomic
DNA was subjected to direct sequencing for the PTHR1 gene (NM_000316.2). Patient data
are resumed in Table 4.1 (patients 17, 19, 21, 22, 24, 25 and 27-31). All coding exons,
including exon-intron boundaries, were amplified according to primers described by Schipani
et al. [24] and with additional primers described in Table 4.2, based on the sequences U22401-
U22409.
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RESULTS
Patient data
In total 41 tumors from 31 patients with enchondromatosis were collected. Clinical details of
all patients are shown in Table 4.1.
PTHR1 immunohistochemistry
Staining results are shown in Table 4.1. Due to loss of attachment of the tissue section from
the slide, as a result of the antigen retrieval procedure, 10 of the 24 samples could not be
evaluated. Eight out of 14 samples were scored as positive for the presence of PTHR1 protein,
five demonstrated only weak positivity, while one tumor was completely negative with a
positive internal control. The staining was mainly found in the nucleus, but cytoplasmic
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staining was also found (Figure 4.1). The results were similar to those obtained for 20 sporadic
chondrosarcoma cases [13].
ASO hybridization: p.R150C PTHR1 mutation
Of the 36 samples from 26 patients (patients 1-26) 33 samples resulted in a PCR product of
the expected size, though the amount of final PCR product varied considerably. The three
samples failing were DNA samples isolated from paraffin embedded tissues, one failing
normal and tumor sample, the third only failing the tumor sample.
Blots containing PCR products from the PTHR1 fragment were hybridized for the mutant
sequence, resulting in strong hybridization signals with intensities that decreased linear
according to a dilution series of PCR products containing the constructed mutant as shown
in Figure 4.2a. However, we did see crosshybridization of the mutant probe with wild type
PCR products that could not be overcome by more stringent hybridization (Figure 4.2a). The
wild-type probe showed strong signals with the wild-type control (placenta DNA from a
healthy donor) and samples, but no crosshybridization with the constructed mutant (Figure
4.2b).
In the dilution experiment the mutant sequence could be detected in a background of wild-
type sequence containing 90% wild-type PCR product and 10% constructed mutant PCR
product. Using this experiment a cut-off value for the probes was determined (0.20). The
signal threshold of the mutant oligonucleotide was defined as the strongest signal obtained
by phosphor imager analysis, for the wild-type control fragment with the mutant
oligonucleotide divided by the signal of the wild-type oligonucleotide for that sample. All
patient samples showed a signal for the mutant oligonucleotide/wild-type oligonucleotide
Figure 4.1: Immunohistochemical staining for the PTHR1 protein. Sample 22.1, an enchondroma of the phalanx,
showing positive PTHR1 expression in both nucleus and cytoplasm of tumor cells. The endothelial cells, serving as
an internal control, also show PTHR1 expression. A: 50x, B: 100x. Color picture can be viewed at page 128
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ratio below this threshold, ranging from 0.03 to 0.19. In contrast, the signal of constructed
mutant, even in a 1 in 10 dilution, was above this threshold (value 0.26).
Sequencing for the p.R150C PTHR1 mutation
A total of 19 samples were selected for sequencing to confirm the results found in the ASO
hybridization. All 19 samples showed the wild-type sequence (reviewed but not shown).
Sequencing of the entire PTHR1 gene
From the 11 patients of whom the whole PTHR1 gene was sequenced, all PCR reactions
resulted in sequencing products. No mutations and/or polymorphisms were detected in the
coding exons of the gene.
DISCUSSION
The PTHR1 protein is important in chondrogenesis and skeletogenesis and is involved in the
IHH/PTHLH feedback loop present in the growth plate [12,25-27]. IHH binds to its receptor
Patched (PTCH) after diffusion, presumably under mediation of heparan sulphate
proteoglycans (HSPG) of which the biosynthesis is mediated by EXT. The binding results in
PTHLH expression which then binds to PTHR1 in the late proliferating zone [28], resulting
in upregulation of BCL2 [27,29]. This signaling regulates the pace of chondrocyte
differentiation by delaying the progression of chondrocytes towards the hyperthrophic zone,
allowing longitudinal bone growth [27].
Deregulation of this feedback loop can result in many different syndromes. For instance, in
patients with Blomstrand Chondrodysplasia (MIM# 215045), inactivating mutations have
been identified in PTHR1 [30], resulting in accelerated chondrocyte differentiation and
premature ossification [31]. In contrast, constitutive active PTHR1 mutations have been
Figure 4.2: ASO hybridization of the samples with labelled α-32P mutant and wild type oligonucleotides. A: Blot
of ASO hybridization with mutant oligonucleotide, b) Blot of ASO hybridization with wild-type oligonucleotide,
showing the same samples as seen in A. constr mut: constructed mutant; wt: wild-type
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identified in patients with Jansen metaphyseal chondrodysplasia (MIM# 156400) [30]. These
patients have a delay in chondrocyte differentiation, in vascular invasion, and a reduction or
absence of mineralization of bone elements that are formed through the endochondral process
[32]. This syndrome shares some radiographical and histological features with
enchondromatosis, like the presence of radiolucent areas containing non calcified cartilage
[33].
In patients with MO mutations in the EXT genes are found, postulated to lead to a
downregulation of the IHH/PTHLH pathway [11,17]. Indeed, in osteochondromas, that are
histologically comparable to the human growth plate, absence of IHH/PTHLH signaling
was demonstrated [13]. Upon malignant transformation of osteochondromas, upregulation
of PTHLH and BCL2 was detected and this was also found during progression of low- towards
high-grade conventional central chondrosarcomas.
Surprisingly, the p.R150C PTHR1 mutation is described to lead to an upregulation of IHH
[16]. It is difficult to understand that both upregulation (in enchondromatosis) and
downregulation (in MO) of the same IHH/PTHLH pathway would cause benign cartilaginous
tumors. We therefore wanted to further investigate PTHR1 in a large series of
enchondromatosis patients. We looked at the PTHR1 protein expression in 14 patients with
enchondromatosis, revealing normal expression in 13 cases. Three of five weakly staining
samples originated from young patients (ages 6, 15 and 23). This suggests that there may be
an age related expression of PTHR1.
The mutation described by Hopyan et al [16] in two of six (33%) enchondromatosis patients
was not found in the 31 enchondromatosis patients that were the subject of this paper.
Sequencing of all exons, including exon-intron boundaries, of the PTHR1 gene in 11 of these
patients also did not reveal any other mutations. The possible presence of an intronic splice
mutation, located outside the sequenced products, is not likely since this would most probably
lead to inactivation of the PTHR1 protein, as seen in Blomstrand’s Chondrodysplasia [34,35],
and not to a receptor with increased signaling, as was described by Hopyan et al [16]. This
indicates that the PTHR1 gene is not involved in Ollier disease and Maffucci syndrome in
our large multinational series. A possible explanation for this discrepancy could be that the
p.R150C PTHR1 mutation described by Hopyan et al. is specific for the Canadian population,
i.e. a founder mutation.
Technically one could argue that the level of contamination with normal tissue in our tumor
samples is just too high for detection of somatic mutations by sequence analysis (in our
samples the tumor percentage was at least 70%). However, the detection level for the p.R150C
PTHR1 mutation using ASO hybridization is high enough to detect even those cases where
the mutated sequence is present in only 10% of the total sample as shown by the dilution
experiment. Thus, with the mutation described by Hopyan et al [16] as being heterozygous,
we should have been able to detect the mutation if it was present.
Another explanation for the discrepancy between the results of Hopyan et al. [16] and our
results may be found in the exact definition of the clinical syndrome, of which the classification
is confusing. Enchondromatosis can be divided using several subclassifications [4-6]. The
two most important ones are Ollier disease and Maffucci syndrome, both accepted by the
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WHO [3]. Extremely rare is spondyloenchondromatosis, which was described to be autosomal
recessive. Its radiographic features include irregular distributed, mostly discrete enchondromas
of long tubular bones and generalized severe platyspondyly with mild or no involvement of
hands and feet [4,36]. Generalized enchondromatosis, with patients having platyspondyly
and metaphyseal manifestations of enchondromatosis with severe involvement of the hands
and feet, has also been described [4,37].
If the patient carrying the germline p.R150C PTHR1 mutation [16], belongs to one of these
rare subclasses of enchondromatosis instead of having Ollier disease, this mutation may be
specific for this rare variant of enchondromatosis. Hopyan et al. [16] describe that one of the
two patients having the p.R150C PTHR1 mutation inherited the mutation from his father,
who had short statue, similar to a patient described by Halal and Azouz [4] diagnosed with
“generalized enchondromatosis” and following an autosomal recessive inheritance pattern.
Our population consisted strictly of patients with Ollier disease or Maffucci syndrome, lacking
platyspondyly after reviewing of clinical charts and radiographs.
In conclusion, in our large, well-characterized, multinational group of enchondromatosis
patients we cannot confirm the involvement of mutations in the PTHR1 gene, indicating that
PTHR1 is not causative for enchondromatosis in contrast to previous reports.
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Absence of IHH and retention of PTHrP signaling in enchondromas and central
chondrosarcomas
LB Rozeman, L Hameetman, AM Cleton-Jansen, AHM Taminiau, PCW Hogendoorn,
JVMG Bovée
Journal of Pathology. 2005; 205 (4): 476-482
Enchondromas and conventional central chondrosarcomas are, respectively, benign and
malignant hyaline cartilage-forming tumors that originate in the medulla of bone. In order to
gain a better understanding of the molecular process underlying malignant transformation of
enchondroma, and to investigate whether there is a biological difference between conventional
central cartilaginous tumors and those of enchondromatosis or with phalangeal localization,
a series of 64 enchondromas (phalanx, n= 21; enchondromatosis, n= 15) and 89
chondrosarcomas (phalanx, n= 17; enchondromatosis, n= 13) was collected. Indian hedgehog
(IHH)/parathyroid hormone related peptide (PTHrP, PTHLH) signaling, an important pathway
in chondrocyte proliferation and differentiation within the normal growth plate, was studied
by immunohistochemical analysis of the expression of PTHLH, PTHR1, BCL2, p21, cyclin
D1 and cyclin E. Quantitative real-time PCR for IHH, PTCH, SMOH and GLI2 was performed
on a subset of tumors. The data show that IHH signaling is absent in enchondromas and
central chondrosarcomas, while PTHLH signaling is active. There was no difference in
expression of any of the molecules between 35 enchondromas and 26 grade I central
chondrosarcomas, indicating that PTHLH signaling is not important in malignant
transformation of enchondroma. Higher expression of PTHR1 and BCL2 was associated
with increasing histological grade in chondrosarcoma, suggesting involvement in tumor
progression. No difference was found between samples from enchondromatosis patients and
solitary cases, suggesting no difference in PTHLH signaling. A small subset of phalangeal
chondrosarcomas demonstrated downregulation of PTHLH, which may be related to its more
indolent clinical behavior. Thus, in both enchondromas and central chondrosarcomas PTHLH
signaling is active and independent of IHH signaling, irrespective of the presence or absence
of enchondromatosis.
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Chondrosarcoma of bone is a malignant tumor characterized by the formation of hyaline
cartilage. The majority (83%) arise centrally within the medullary cavity of bone (primary
conventional central chondrosarcomas)[1]. Transformation of enchondroma, a benign
cartilaginous tumor, towards secondary central chondrosarcoma is thought to be very rare
(<1% of enchondromas)[1,2], and the mechanism underlying malignant transformation is
unknown. In about 40% of central chondrosarcomas, remnants of a previous, often undetected,
enchondroma are found next to the chondrosarcoma, implying that these cases are strictly
not primary, but secondary chondrosarcomas. Since these remnants are difficult to detect, it
may be that all central chondrosarcomas are secondary [3].
About 50% of enchondromas are found in small bones of hands and feet, while
chondrosarcomas are rare at this location [2] and, in contrast to elsewhere, only rarely
metastasize [4]. This raises the question whether cartilaginous tumors with phalangeal
localization are biologically different, or whether localization determines prognosis.
While most enchondromas are solitary, patients with enchondromatosis (Ollier disease,
Maffucci syndrome) have multiple enchondromas, scattered all over the skeleton, often with
unilateral predominance [5]. The percentage of malignant transformation in patients with
enchondromatosis is much higher (25-30% per patient) than in patients with solitary
enchondromas [1,2]. For enchondromas with phalangeal localization, as well as enchondromas
from enchondromatosis patients, more worrisome histological features are tolerated [1,2],
since they clinically behave in a more indolent fashion.
The aims of our study were, firstly, to gain a better understanding of the molecular process
underlying malignant transformation of enchondroma and, secondary, to investigate possible
biological differences between conventional central cartilaginous tumors and those within
the context of enchondromatosis or with phalangeal localization.
Within the normal growth plate, the Indian hedgehog (IHH)/parathyroid hormone related
peptide (PTHrP, PTHLH) negative feedback loop plays an important role in the regulation of
chondrocyte growth and differentiation [6-12] (Figure 5.1). We investigated molecules
involved in PTHLH signaling by comparing the protein expression of these signaling
molecules between the different subsets of tumors and assessed whether putative differences
in this signaling pathway are associated with different clinical behavior. Since commercially
available antibodies for IHH signaling molecules have been shown previously not to work
reliably in our hands [13], expression was studied with quantitative RT-PCR in a subset of
tumors to evaluate their role in tumorigenesis and tumor progression.
MATERIALS AND METHODS
Pathological material
Formalin-fixed, paraffin wax-embedded material was used from 153 tumors (Table 5.1).
Cases were collected from (consultation) files of the Leiden University Medical Center.
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Patient data (Table 5.1) were obtained by review of pathological specimens and reports,
clinical charts and radiographs. Enchondromatosis was found in 28 patients. Histological
grading for non-phalangeal cases was performed according to Evans et al [14]. Clinico-
pathological features of phalangeal chondrosarcomas have been described previously [4].
All tissue samples were handled in a coded fashion, according to national ethical guidelines
(“Code for Proper Secondary Use of Human Tissue in The Netherlands”, Dutch Federation
of Medical Scientific Societies).
Figure 5.1: Signaling within the normal human growth plate. Indian Hedgehog (IHH), produced by pre-hyper-
trophic chondrocytes, binds after diffusion mediated by heparan sulphate proteoglycans (HSPG), to its receptor
Patched (PTCH). This results in the release of Smoothened (SMOH) from PTCH, which allows GLI molecules to
act as transcriptional activators of target genes [6]. These include genes from the IHH pathway itself, such as
PTCH and GLI [6,7]. Two other target genes are Cyclin E [8], involved in control of the transition of G1 to S-
phase, and parathyroid hormone related peptide (PTHrP, PTHLH)[9]. PTHLH binds to its receptor (PTHR1) in
the late proliferating zone, resulting in up-regulation of the anti-apoptotic protein BCL2 [10]. This inhibits further
differentiation, thereby limiting IHH-producing cells, closing the negative feedback loop. Moreover, PTHR1 di-
rectly induces activation of the Cyclin D1 promoter [11]. FGFR3 activation leads to repression of IHH/PTHLH
signaling, and to up-regulation of the cell cycle inhibitor p21 [12]. The molecules investigated in this study are
underlined
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Immunohistochemistry
Antibodies, controls, and antigen retrieval are described in Table 5.2. Antibodies were tested
for their susceptibility to formalin fixation on appropriate tissues fixed for 1, 3, 7, and 40
days, respectively, but none revealed diminished staining reactivity. Internal positive controls
were used (Table 5.2) to exclude absence of staining due to decalcification. Negative controls
were performed using isotype controls. Immunohistochemical staining was performed as
described previously [13].
Evaluation and Scoring
Three observers (LBR, PCWH and JVMGB) evaluated the slides independently and
discrepancies were discussed. All observers were blinded towards clinico-pathological data.
Scoring was performed as described [13]. In short, staining intensities (0= negative, 1= weak,
2= moderate and 3= strong intensity) and percentage of positive cells (0= 0%, 1= 1-24%,
2=25-49%, 3= 50-74% and 4= 75-100% positive) were assessed. The slides were scored
positive if the combined values of staining intensity and percentage of positive cells were
greater than 3 for PTHLH, PTHR1 and BCL2 and greater than 0 for p21, Cyclin D1 and
Cyclin E [13,15,16]. For Cyclin E and cyclin D1, lacking an absolute internal control, cases
were only scored negative if immunohistochemical data were available for at least four other
antibodies.
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RNA isolation and quantitative PCR (qPCR)
RNA was isolated from 10 tumors [2 phalangeal enchondromas (enchondromatosis patients),
1 solitary grade I chondrosarcoma, 5 grade II chondrosarcomas (3 from enchondromatosis
patients), and 2 solitary grade III chondrosarcomas] and 7 normal samples (4 growth plates
and 3 normal resting cartilage samples) as described previously [17].
One micorgram of total RNA was converted to complementary DNA (cDNA) by using AMV
Reverse Transcriptase (Roche Applied Science). qPCR was performed for IHH, PTCH,
SMOH, GLI2, and four normalization genes (CPSF6, GPR108, HNRPH1 and SRPR; primers
and qPCR conditions available on request). The latter were selected from expression profiling
experiments of enchondromas, central chondrosarcomas (different grades), normal epiphyseal
growth plates and resting cartilage samples, demonstrating the least variation between all
samples (unpublished data). qPCR amplification was performed according to manufacturer’s
protocol. For each gene a standardcurve, consisting of a mixture of eight samples, was included
to calculate the relative starting quantity of each gene, which was used in normalization and
statistical analysis.
Geometric averaging of the candidate normalization genes [18] was performed to acquire
reliable normalization of the qPCR experiments. This method provides a normalization factor
(NF), representative for the amount of mRNA in each sample. Expression levels in the tumors
were related to those of four normal growth plates, where IHH signaling is known to be
active [9].
Statistical analysis
Comparison of immunohistochemical data between two different groups was analyzed using
Pearson chi-Square/Fisher’s exact test, two-sided. Correlation between staining and
histological grade was tested with chi-square, linear by linear. Correlation with outcome was
analyzed using log-rank test. To correct for multiple testing, p values ≤ 0.01 were considered
significant. Relative RNA expression levels from the different tumor groups were compared
to growth plates by one-way ANOVA with Bonferroni correction, after log transformation.
A p value ≤ 0.05 was considered significant.
RESULTS
Immunohistochemistry
PTHLH signaling molecules are present in enchondromas and central chondrosarcomas.
p21 and PTHLH were positive in almost all samples, whereas PTHR1, BCL2 and cyclin D1
showed more variation (Table 5.3). Cyclin E was only minimally positive in 4 of 88 samples
and therefore not used in further statistical analysis. A variable number of samples, ranging
from 11 (PTHLH) to 29 (Cyclin D1), could not be evaluated due to detachment to the glass
slides.
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Statistical analysis of immunohistochemistry
Enchondroma vs chondrosarcoma grade I
No significant difference was found for any of the investigated molecules between 35 non-
phalangeal solitary enchondromas and 26 solitary conventional central chondrosarcomas
grade I (p = 0.066 - 1.00); between the 21 enchondromas of the phalanx and 17
chondrosarcomas of the phalanx [p=0.035 (PTHLH) - 1.00]; or between 15 enchondromas
and 13 chondrosarcomas in patients with enchondromatosis (p = 0.267-1.00).
Phalangeal localization vs localization elsewhere
Phalangeal chondrosarcomas were compared with grade II conventional central
chondrosarcomas located elsewhere, based on similar histological features [4]. Only PTHLH
differed significantly, being expressed in 12 of 16 (75%) phalangeal chondrosarcomas
compared with 100% (n = 25) of chondrosarcomas grade II located elsewhere (p = 0.010)
(Figure 5.2).
In addition, expression of BCL2 was found in 9 of 13 (69%) solitary phalangeal enchondromas
compared with 4 of 25 (16%) solitary enchondromas located elsewhere, (p = 0.001). A trend
63
IHH and PTHLH signaling in central chondrosarcomas
Figure 5.2: Lack of PTHLH expression in a subset of phalangeal chondrosarcomas. (A) PTHLH expression is
absent in a phalangeal chondrosarcoma, with a positive internal control (inset), while (B) strong expression of
PTHLH is found in grade II chondrosarcoma. Color picture can be viewed at page 129
Figure 5.3: Immunohistochemical staining for BCL2 and PTHR1 in low- and high-grade conventional central
chondrosarcoma. PTHR1 (A, B) and BCL2 (C, D) staining shows low intensity and a low percentage of positive
cells in grade I conventional central chondrosarcomas (A and C, arrows), while increased staining is found in
high-grade conventional central chondrosarcomas (B and D, grade III). Color picture can be viewed at page 129
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was found towards higher expression for PTHR1 in all phalangeal enchondromas [13 of 18
(72%) positive] compared to all enchondromas elsewhere [9 of 23 (39%) positive] was found
(p=0.072).
Enchondromatosis vs solitary cases
Expression was compared both for all tumors together and for each subtype separately (eg
enchondroma; enchondroma of the phalanx; chondrosarcoma grade I, II, and III). No
difference was observed for any of the proteins.
Low-grade vs high-grade conventional central chondrosarcomas
Analyzing all samples, increased PTHR1 and BCL2 expression correlated with increasing
histological grade (p=0.002 and p=0.000, respectively; Figure 5.3). For BCL2, this was
mainly based on the increased percentage of positive cells (p=0.000), while for PTHR1,
both the intensity and the percentage of cells increased (both p=0.000). Histological grade
was correlated with disease-free or metastasis-free survival (p<0.0000 for both parameters),
but none of the molecules was an independent significant predictor of outcome.
Correlation between expression of the different proteins
A positive correlation was found between BCL2 and PTHR1 (p=0.000).
qPCR
Expression of IHH, PTCH, GLI2 and SMOH was present in the growth plate specimens.
Expression of PTCH, which can be used as a read-out system for HH activity, and GLI2 was
dramatically decreased in the tumors as compared with the normal growth plate (Table 5.4).
Although the sample size is small, PTCH expression was lower in normal cartilage (p=0.019),
chondrosarcoma grade II (p=0.000) and III (p=0.000) and GLI2 expression lower in
chondrosarcoma grade II (p=0.020) and III (p=0.013) compared with growth plates. No
differences were found comparing solitary and enchondromatosis-related samples.
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DISCUSSION
In this study, we have demonstrated active PTHLH signaling in both enchondroma and central
chondrosarcoma by protein expression of PTHLH, PTHR1, BCL2 and Cyclin D1. Expression
of PTCH RNA was very low or absent. Activation of IHH signaling leads to the activation of
target genes, including PTCH and GLI [6,7]. Therefore, transcriptional activation of PTCH
is used as reporter for Hedgehog signaling [6]. The absence of PTCH thus indicates that IHH
signaling is not active in enchondroma and central chondrosarcoma. In Drosophila, cyclin E
is downstream of Hedgehog [8]. We detected cyclin E expression in only four samples,
indicating that this molecule is not very important in the development of enchondromas and/
or chondrosarcomas, which corroborates the absence of IHH signaling. Thus, PTHLH
signaling in enchondroma and central chondrosarcoma is not activated by IHH but by other,
as yet unknown, mechanisms. TGF-beta is a good candidate since it was reported to induce
PTHLH [19] and is expressed in chondrosarcoma [20].
Our findings confirm the importance of PTHLH signaling in cartilage neoplasia, as previously
shown in chondroblastoma [15] and secondary peripheral chondrosarcoma [13]. Since no
difference was found between enchondroma and chondrosarcoma, it seems that PTHLH
signaling does not play a vital role in malignant transformation of enchondroma towards
secondary central chondrosarcoma.
About 17% of chondrosarcomas develop within the cartilaginous cap of a pre-existing benign
osteochondroma (secondary peripheral chondrosarcomas) [21]. In osteochondromas, PTHLH
signaling is absent [13], most likely due to mutational inactivation and/or loss of EXT genes
[22]. Upon malignant transformation PTHLH and BCL2 expression is upregulated [13].
This makes absence of PTHLH signaling specific for osteochondromas since PTHLH
signaling is active in enchondromas and chondroblastomas [15].
We have confirmed that higher BCL2 expression is associated with progression towards
high-grade central chondrosarcoma, as suggested by our previous results [13]. BCL2
negatively controls programmed cell death both in growth plate chondrocytes in situ and in
vitro [10]. Expression of PTHR1, using a monoclonal antibody, correlated with increasing
histological grade, which was not found with the polyclonal antibody used in our earlier
pilot series [13].
In the present study, PTHLH was expressed in almost all samples, while previously [13]
expression seemed to increase with grade. However, this was done using a much smaller
sample size and a different batch of the polyclonal antibody. Although no distinction between
central and peripheral tumors was made, expression of PTHLH and PTHR1 has also been
examined by others, showing up-regulation with grade [23,24]. Thus, in enchondroma and
central chondrosarcoma PTHLH signaling is active and seems to increase with histological
grade, in parallel with the increased proliferative activity.
One of our goals was to investigate whether phalangeal cartilaginous tumors are biologically
different from other sites. Phalangeal chondrosarcomas display locally aggressive behavior
with very low metastatic potential (<2%)[4]. Remarkably, only 4 of 142 tumors were PTHLH
negative and all four were chondrosarcomas of the phalanx. This down-regulation of PTHLH
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signaling which is also found in osteochondroma [13] may be specific for at least a subset of
phalangeal chondrosarcomas and may be related to their more indolent behavior. Combined
with the slightly lower proliferation rate and slightly lower percentage of p53 overexpression
in phalangeal chondrosarcomas reported previously [4] these data support the suggestion
that chondrosarcomas of the phalanx are indeed biologically different.
Expression of BCL2 and PTHR1 was higher in solitary phalangeal enchondromas than in
solitary enchondromas elsewhere. Since PTHR1 and BCL2 correlates with increasing
histological grade in non-phalangeal chondrosarcomas, these results probably are associated
with the more worrisome histological features tolerated in phalangeal enchondroma, but
leading to a diagnosis of chondrosarcoma at other localizations [1,2].
Finally, no differences were found between solitary and enchondromatosis-related tumors.
An activating mutation has been reported in PTHR1 in two enchondromatosis patients [25].
The mutation would lead to up-regulation of IHH signaling [25]. Here we demonstrate absence
of IHH signaling in two enchondromas and three chondrosarcomas of enchondromatosis
patients. In addition, we previously screened 31 patients and could not find any PTHR1
mutations [26]. These data again indicate that PTHR1 is not the culprit for enchondromatosis.
p21 was expressed in the majority of tumors. p21 inhibits chondrocyte proliferation, reducing
the number of IHH-expressing cells in the growth plate [12]. There may be a role for p21 in
the downregulation of IHH signaling that we observed.
In conclusion, we demonstrate that IHH signaling is absent in enchondromas and central
conventional chondrosarcomas, indicating that although this pathway is important in normal
chondrocyte growth and differentiation, it is not involved in enchondromas and
chondrosarcomas. However, PTHLH signaling is active in both enchondromas and
conventional central chondrosarcomas, confirming its importance in growth and differentiation
of neoplastic cartilage and suggesting activation independent of IHH signaling.
ACKNOWLEDGEMENTS
The authors would like to thank HM v Beerendonk, IH Briaire-de Bruijn, A Yavas and S Keshtkar for expert
technical assistance; S Romeo for fruitful discussions; and P Eilers for help with statistical analysis. This research
was supported by ZON MW (grant nr. 908-02-018), the Optimix Foundation and the Centre for Medical Systems
Biology (NWO).
REFERENCE LIST
1. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors.
World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and
bone. Lyon: IARC Press, 2002: 247-251.
2. Lucas DR, Bridge JA. Chondromas: enchondroma,periosteal chondroma,and enchondromatosis. In: Fletcher
CDM, Unni KK, Mertens F, editors. World Health Organization classification of tumours. Pathology and ge-
netics of tumours of soft tissue and bone. Lyon: IARC Press, 2002: 237-240.
3. Brien EW, Mirra JM, Kerr R. Benign and malignant cartilage tumors of bone and joint: their anatomic and
theoretical basis with an emphasis on radiology, pathology and clinical biology I. The intramedullary cartilage
tumors. Skeletal Radiol 1997; 26:325-353.
4. Bovée JVMG, Van der Heul RO, Taminiau AHM, Hogendoorn PCW. Chondrosarcoma of the Phalanx: a
locally aggressive lesion with minimal metastatic potential. A report of 35 cases and a review of the literature.
Cancer 1999; 86:1724-1732.
67
IHH and PTHLH signaling in central chondrosarcomas
5. Mertens F, Unni KK. Enchondromatosis: Ollier disease and Maffucci syndrome. In: Fletcher CDM, Unni KK,
Mertens F, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours
of soft tissue and bone. Lyon: IARC Press, 2002: 356-357.
6. Alexandre C, Jacinto A, Ingham PW. Transcriptional activation of hedgehog target genes in Drosophila is
mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding
proteins. Genes Dev 1996; 10(16):2003-2013.
7. Chuang P-T, McMahon AP. Vertebrate hedgehog signalling modulated by induction of a hedgehog-binding
protein. Nature 1999; 397:617-621.
8. Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing Cyclin
D and Cyclin E. Nature 2002; 417(6886):299-304.
9. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differen-
tiation by indian hedgehog and PTH-related protein. Science 1996; 273:613-622.
10. Amling M, Neff L, Tanaka S, Inoue D, Kuida K, Weir E et al. Bcl-2 lies downstream of parathyroid hormone
related peptide in a signalling pathway that regulates chondrocyte maturation during skeletal development. J
Cell Biol 1997; 136:205-213.
11. Beier F, LuValle P. The cyclin D1 and cyclin A genes are targets of activated PTH/PTHrP receptors in Jansen’s
metaphyseal chondrodysplasia. Mol Endocrinol 2002; 16(9):2163-2173.
12. Sahni M, Ambrosetti D-C, Mansukhani A, Gertner R, Levy D, Basilico C. FGF signaling inhibits chondrocyte
proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 1999; 13:1361-1366.
13. Bovée JVMG, Van den Broek LJCM, Cleton-Jansen AM, Hogendoorn PCW. Up-regulation of PTHrP and
Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is
a late event in central chondrosarcoma. Lab Invest 2000; 80:1925-1933.
14. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic
analysis with emphasis on histologic grading. Cancer 1977; 40:818-831.
15. Romeo S, Bovée JVMG, Jadnanansing NAA, Taminiau AHM, Hogendoorn PCW. Expression of cartilage
growth plate signalling molecules in chondroblastoma. J Pathol 2004; 202(1):113-120.
16. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A et al. EGFR, HER-2/neu,
cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carci-
noma in situ of the breast. Breast Cancer Res Treat 2003; 79(2):187-198.
17. Baelde HJ, Cleton-Jansen AM, van Beerendonk H, Namba M, Bovée JVMG, Hogendoorn PCW. High quality
RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays:
application to chondrosarcoma. J Clin Pathol 2001; 54(10):778-782.
18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-
time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;
3(7):research0034.1-0034.11.
19. Alvarez J, Sohn P, Zeng X, Doetschman T, Robbins DJ, Serra R. TGFbeta2 mediates the effects of hedgehog
on hypertrophic differentiation and PTHrP expression. Development 2002; 129(8):1913-1924.
20. Masi L, Malentacchi C, Campanacci D, Franchi A. Transforming growth factor-beta isoform and receptor
expression in chondrosarcoma of bone. Virchows Arch 2002; 440(5):491-497.
21. Khurana J, Abdul-Karim F, Bovée JVMG. Osteochondroma. In: Fletcher CDM, Unni KK, Mertens F, editors.
World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and
bone. Lyon: IARC Press, 2002: 234-236.
22. Bovée JVMG, Hogendoorn PCW. Multiple osteochondromas. In: Fletcher CDM, Unni KK, Mertens F, editors.
World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and
bone. Lyon: IARC Press, 2002: 360-362.
23. Kunisada T, Moseley JM, Slavin JL, Martin TJ, Choong PF. Co-expression of parathyroid hormone-related
protein (PTHrP) and PTH/PTHrP receptor in cartilaginous tumours: a marker for malignancy? Pathology 2002;
34(2):133-137.
24. Pateder DB, Gish MW, O’Keefe RJ, Hicks DG, Teot LA, Rosier RN. Parathyroid hormone-related Peptide
expression in cartilaginous tumors. Clin Orthop 2002;(403):198-204.
25. Hopyan S, Gokgoz N, Poon R, Gensure RC, Yu C, Cole WG et al. A mutant PTH/PTHrP type I receptor in
enchondromatosis. Nat Genet 2002; 30(3):306-310.
26. Rozeman LB, Sangiorgi L, Briaire-de Bruijn IH, Mainil-Varlet P, Bertoni F, Cleton-Jansen A-M et al.
Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Hu-
man Mutation 2004; 24:466-473.
68
Chapter 5
69
Expression profiles of central chondrosarcoma
Chapter 6
cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary
tumors and alteration in genes coding for components of energy metabolism occurs
with increasing grade
LB. Rozeman, L Hameetman, T van Wezel, AHM Taminiau, AM Cleton-Jansen, PCW
Hogendoorn, JVMG Bovée
Journal of Pathology. 2005; 207(1): 61-71
Conventional central chondrosarcomas are malignant cartilaginous tumors, occasionally
arising secondary to either solitary or multiple (Ollier disease) enchondromas. Recurrences
may have progressed in grade. The aims of the present study were to identify putative
differences in gene expression between solitary and Ollier disease-related tumors, and to
elucidate signaling pathways involved in tumor progression by genome-wide cDNA
expression analysis. Arrays enriched for cartilage-specific cDNAs and genes involved in
general tumorigenesis were used to analyse enchondromas (n = 3, two with Ollier disease),
chondrosarcomas of different grades (n = 19, three with Ollier disease), normal resting-zone
cartilage (n = 2) and chondrosarcoma cells in culture (n = 7). The arrays were analyzed by
unsupervised hierarchical clustering, significant analysis of microarray and T-tests.
Confirmation of data was performed by immunohistochemistry and quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR). Ollier disease cases and solitary tumors
revealed similar expression profiles, suggesting that the same signaling pathways are involved
in tumorigenesis. Interestingly, JUNB protein expression was significantly higher in grade I
chondrosarcomas than enchondromas (p = 0.009), which could be of diagnostic relevance.
Upon chondrosarcoma progression, matrix-associated genes are down-regulated, reflecting
the histology of high-grade tumors. An increase of glycolysis-associated, and a decrease of
oxidative phosphorylation-related, genes was found in high-grade tumors. These findings
suggest an adaptation in energy supply upon progression towards higher grade.
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Chondrosarcoma of bone is a malignant hyaline cartilage-forming tumor that affects males
and females equally, with a peak incidence around the fifth decade [1]. Most chondrosarcomas
(~ 83%) arise centrally within the medulla and can develop from a pre-existing enchondroma
[1]. A minority (~17%) are located at the surface of bone (secondary peripheral
chondrosarcomas) [1,2].
While most enchondromas are solitary, patients with Ollier disease (enchondromatosis) have
multiple enchondromas, scattered throughout the skeleton, often with a unilateral
predominance [3]. Enchondromas of Ollier disease patients display a more indolent clinical
behavior. These enchondromas can contain more worrisome histological features (higher
cellularity, pleomorphism and binucleated cells), compared to solitary enchondromas [3,4].
The overall risk of malignant transformation in patients with Ollier disease is higher and has
been estimated at 25-30%, compared to less than 1% for solitary enchondromas [3].
Three histological grades of malignancy are distinguished [5]. Increasing grade correlates
with worse prognosis [5,6]. The fact that recurrences of chondrosarcomas can exhibit a higher
grade of malignancy compared to previous lesions suggests that these tumors may progress
[5,7].
Little is known about the pathways involved in the development and progression of central
chondrosarcomas. Loss of heterozygosity (LOH) analysis shows limited changes, with some
recurrent LOH at 9p21 [8]. Increased PTHLH (parathyroid hormone like hormone) signaling
is present in high-grade tumors [9,10]. p53 overexpression and mutations [8,11], as well as
absence of p16/INK4A [12,13], are also found to correlate with high histological grade.
For Ollier disease, case reports describe an interstitial deletion at chromosomal region 1p
[14], LOH at 13q14 and 9p21, and p53 overexpression [15]. Hopyan et al.[16] reported a
mutation, p.R150C, in the PTHR1 (parathyroid hormone receptor 1) gene in two of six patients
with Ollier disease: this mutation was absent in 50 solitary chondrosarcomas and 100
unaffected individuals. However, in a larger, multi-institutional series of 31 Ollier disease
patients, this specific mutation was not identified, nor did sequencing the entire gene in 11
patients reveal any other mutations [17]. Moreover, in contrast to the up-regulation of IHH
(indian hedgehog) signaling due to PTHR1 mutations claimed by Hopyan et al.[16], we
demonstrated that IHH signaling was very low or absent, while PTHLH signaling was active
in both Ollier disease and solitary tumors [10].
We wanted to investigate whether Ollier disease tumors have a distinct gene expression
profile when compared with solitary tumors by cDNA microarray analysis, to find an
explanation for the clinical differences. To elucidate the pathways involved in progression
of chondrosarcomas, we compared gene expression levels between low- and high-grade
chondrosarcomas.
MATERIAL AND METHODS
Clinical Samples
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Fresh frozen enchondroma and conventional central chondrosarcoma samples were collected
from the archives of the Department of Pathology of the Leiden University Medical Center.
Twenty-two tumor samples (3 enchondromas, 7 grade I, 7 grade II, and 5 grade III
chondrosarcomas), five of which Ollier disease-related (two enchondromas, and three grade
II chondrosarcomas), and two normal resting-zone cartilage samples were used (Table 6.1).
In addition, two chondrosarcoma cell lines and five primary chondrosarcoma cell cultures
were used (1 grade I, 3 grade II, and 3 grade III). All enchondroma specimens were of
phalangeal localization, which should be regarded a separate subgroup because of their more
worrisome histological features compared with enchondromas elsewhere [18]. All specimens
were handled according to the ethical guidelines as described in “Code for Proper Secondary
Use of Human Tissue in The Netherlands”, Dutch Federation of Medical Scientific Societies.
Reference Panel
As a common reference panel, used to compare cDNA array experiments, 15 highly diverse
cancer cell lines were used, of which eight cell lines were selected from Scherf et al.[19]
[HL-60 (acute myeloid leukemia); NCI-H226 (non-small-cell-lung); COLO 205 (colon);
SB-19 (central nervous system); CAKI-1 (renal); OVCAR-3 (ovarian); PC-3 (prostate), MCF7
(breast)]. In addition, SAOS-2 and MG-63 (osteosarcoma), OUMS-27 and SW1353
(chondrosarcoma), and three additional primary central chondrosarcoma cell cultures were
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added as samples expressing bone and cartilage-specific genes. RNA from all cell lines was
mixed in equal amounts.
RNA isolation
For RNA isolation, we used samples containing at least 70% of tumor cells, as estimated on
haematoxylin and eosin-stained frozen sections. RNA was isolated as previously described
[20]. The amount of RNA was determined with a spectrophotometer and the integrity of the
RNA was assessed by gel electrophoresis of 0.5-1.0 µg RNA on a 1% agarose/formalin gel.
cDNA microarray analysis
A cDNA array was designed containing 8696 cDNA clones, representing common genes
and a selection of genes (~500) known to be expressed in cartilage, growth plate or involved
in carcinogenesis in general (genelist available on request). Most of these genes were selected
from the sequence-verified human ResGen 40K library (Research Genetics, Invitrogen,
Huntsville, AL, USA); others were ordered from DKFZ (RZPD, Berlin, Germany) or custom
made. For these clones, cDNA primers were derived from the reference sequence from NCBI.
RT-PCR reactions were performed on RNA from tissue samples reported to express these
genes (http://cgap.nci.nih.gov/Genes/GeneFinder). PCR-products were cloned in a vector
using TOPO TA Cloning (Invitrogen) and verified by sequencing. All clones were PCR-
amplified [21] and verified for size on a 1% agarose gel. After precipitation, PCR products
were dissolved in 40 µl 3x SSC.
The arrays were printed on Micromax SuperChip glass slides (Perkin Elmer, Wellesley, MA,
USA) using an OmniGrid 100 (GeneMachines, San Carlos, CA, USA) in a 2 x 8 printer tip
configuration according to manufacturer’s protocol. All clones were printed in duplicate.
Hybridization
One µg of total RNA from the samples was labeled with biotin and 1 µg of reference panel
total RNA with fluorescein, generating biotin and fluorescein-labeled cDNAs with the
Micromax TSA Labeling Kit (Perkin Elmer) according to the supplied protocol. Slides were
hybridized with labeled cDNAs in Corning hybridization chambers (Corning, NY, USA).
TSA detection was done using Shandon cover plates (Thermo Shandon, Thermo Electron
Corporation, Waltham, MA, USA).
Scanning and spot analysis
Following hybridization, arrays were scanned using a GeneTac LSV scanner (Genomic
Solutions, Ann Arbor, MI, USA). To collect as many data as possible from both weakly and
strongly expressed genes, two images were made with a different scanning intensity (gain)
for each dye.
The intensity of the fluorescent signals (Cy3 and Cy5) was collected in four different images
(high and low gain) and quantified with Genepix Pro 4.1 software (Axon Instruments, Union
City, CA, USA). A Microsoft Excel macro was applied that systematically selects bona fide
spotted clones from Genepix data. In this macro, the spot diameter (>70 µm), signal above
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background (>500 counts), saturation (<10%), and the ratio between low and high gain scans
were criteria to select valid spotted clones. Signals were normalized by dividing through the
median signal per array. Next, the log10 transformed Cy3/Cy5 ratio for both high and low
gain scans was calculated for the valid spotted clones. Finally, the data from high and low
gain scans were averaged, resulting in a single log10 ratio for each valid spot.
The PCR products of spotted clones that were identified as significantly different were
sequence-verified.
Statistical analysis of microarray data
The arrays were analyzed by unsupervised hierarchical clustering and comparison of groups
using the Spotfire Decisionsite for functional genomics (Somerville, MA, USA). Data
from samples that were hybridized twice, either as duplicate or dye swap, were averaged.
Normalized data were used for further analysis. Additional analysis of differential gene
expression between two groups was performed with significance analysis of microarray (SAM)
[22]. The global testing method was used to find differentially expressed categories of genes
between two groups [23]. To correct for multiple testing, a false discovery rate (FDR) of
10% was accepted, using a step-up procedure [24].
Quantitative reverse transcriptase PCR (Q-PCR)
Nineteen samples (3 normal cartilage, 2 phalangeal enchondromas, 1 grade I, 8 grade II and
5 grade III chondrosarcomas) were used for verification of array data. Five of these (1 normal
cartilage, 2 grade II and 2 grade III chondrosarcomas) had not been used previously for
hybridization. One µg of total RNA was reverse transcribed with AMV Reverse Transcriptase
(Roche). Primers were designed for the selected genes (Supplementary table 6.1). For each
gene, a calibration curve, consisting of a mixture of eight samples, was included to allow
calculation of relative starting quantities of each gene. These were used in the normalization
and statistical analysis.
Candidate genes for normalization were selected from array results demonstrating the least
variation between all samples (Supplementary table 6.1). Normalization was based on
geometric averaging of the candidate normalization genes, as previously described [25], to
acquire a reliable normalization of the Q-PCR experiments. This method provides a
normalization factor (NF), representative of the amount of mRNA in each sample.
Immunohistochemistry
An intron-exon boundary is absent from JUNB, making the distinction between RNA and
DNA difficult, if not impossible. JUNB protein expression (sc-8051, Santa Cruz Biotech-
nology, Inc., dilution 1:200) was tested in a large group of paraffin-embedded enchondro-
mas and chondrosarcomas described previously [10]. Staining intensities (0 = negative, 1 =
weak, 2 = moderate and 3 = strong intensity) and the percentage of positive cells (0 = 0%, 1
= 1-24%, 2 =25-49%, 3 = 50-74% and 4 = 75-100% positive) were assessed [9]. Osteoblasts
and osteoclasts were used as a positive internal control. A sum score of more than 3 was
considered positive, excluding samples with only sporadic positive cells.
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RESULTS
cDNA microarray
Verification of array quality
All samples were first analyzed by unsupervised hierarchical clustering. All duplicate
experiments (including dye swaps) clustered together (Figure 6.1a), indicating technical
reproducibility and absence of a dye effect. Duplicate samples were averaged in further
analysis. The two normal cartilage samples clustered together (Figures 6.1a and b). No distinct
clusters of the tumor samples were found, indicating that more subtle changes in gene
expression characterize the different histological grades. Chondrosarcoma cell lines and
cultures clustered separately from primary tissues, reflecting, for instance, the decrease of
Figure 6.1: Unsupervised hierarchical clustering of the samples. (A) Hierarchical clustering on the array includ-
ing the samples that were hybridized in duplicate, which cluster together (black horizontal bars). The cell lines/
cultures cluster separately from the primary samples. The samples from normal cartilage also cluster together and
form a separate cluster (dotted box). Note that the hybridizations of the paired solid tumor and primary cell
cultures from the two samples for which these were available (L869 and L835) do not cluster together. (B) Hierar-
chical clustering of the arrays, excluding the cell lines, after averaging of the duplicate hybridizations. CS: chon-
drosarcoma; I: grade I; II: grade II; III: grade III; EC-P: phalangeal enchondroma; OD: Ollier disease
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extracellular matrix and increased proliferation. The cells were, however, still of cartilaginous
origin, demonstrated by low expression of cartilage-specific genes (aggrecan, collagen II
and SOX9). This probably reflects the “dedifferentiation” described in cultivated articular
chondrocytes [26]. Duplicate spotted clones correlated significantly with each other. These
data suggest that this home-made array is potentially able to distinguish biological samples
on the basis of their expression profile.
Sequencing of selected clones (~140) revealed that ~90% of the clones were correct. The
other products contained the wrong sequence or PCR analysis revealed multiple bands,
indicating contamination.
Ollier disease versus sporadic central chondrosarcomas
The analysis of Ollier disease-associated versus solitary tumors was initially performed using
the grade II chondrosarcoma samples (n = 7, three with Ollier disease). Identified genes
were subsequently analyzed in solitary and Ollier disease-related phalangeal enchondromas.
SAM analysis revealed no differentially expressed genes. Group comparison (option
“treatment comparison” from the Spotfire Decisionsite for functional genomics) with
cDNAs present in at least 80% of all samples demonstrated a difference. In total, 68 genes
(81 spotted clones) demonstrated a p < 0.05 (T-test, two-sided); 26 genes (37 spotted clones)
were expressed more highly; and 42 genes (43 spotted clones) were expressed at a lower
level, in Ollier disease samples (Supplementary table 6.2). For 28 of these genes (38 spotted
clones, 47.5%) three phalangeal enchondromas (1 solitary and 2 Ollier disease-related) showed
similar results. Amongst these were genes as JUNB, MYC and CYR61. For five genes (6%),
this information was not available because the spotted clones did not give a bona fide signal
on the arrays of phalangeal tumors. However, the differences in expression between grade II
Ollier disease and solitary chondrosarcomas were not statistically significant after correction
by FDR (false discovery rate).
To find pathways, we performed global testing, using gene ontology terms, revealing seven
groups of genes differentially expressed (p values ranging between 0.005-0.031,
Supplementary table 6.3). None was significant after correction by FDR. Thus, by microarray
analysis the Ollier disease samples used here did not reveal an expression pattern that was
significantly different from solitary tumors.
Low-grade versus. high-grade central chondrosarcomas
To study tumor progression, seven grade I and five grade III chondrosarcomas were compared.
The most optimal SAM analysis resulted in 14 differentially expressed genes corresponding
to 21 spotted clones with 1 false positive. Eleven genes (17 spotted clones) were more highly
expressed and three (four spotted clones) were expressed to a lower level in grade III samples
(Table 6.2). In general, grade II tumors showed an expression level for these genes intermediate
to grade I and III samples. Remarkably, the phalangeal enchondromas had expression levels
that were generally ranging between those of grade I and grade II chondrosarcomas. As
expected, genes involved in the extracellular matrix, such as COL9A2 (collagen, type IX,
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alpha 2) and COL2A1 (collagen, type II, alpha 1) showed a trend towards down-regulation in
grade III chondrosarcomas (p = 1.5E-04 and 3.7E-10, respectively).
MTCYB (mitochondrial cytochrome B), involved in oxidative phosphorylation (OXPHOS),
was expressed to a lower level in grade III chondrosarcomas (p = 5.9E-09). Multiple clones
from ALDOA (aldolase A, n =3) and GAPD (glyceraldehyde-3-phosphate dehydrogenase, n
=4), both involved in glycolysis, were expressed more highly in grade III samples (p = 2.6E-
07 and p = 1.2E-07, respectively). Multiple clones of PLOD3 (procollagen-lysine, 2-
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oxoglutarate 5-dioxygenase 3, n = 2), a matrix associated gene, showed up-regulation in
grade III tumors (p = 6.0E-06).
Global testing, using gene ontology terms, identified 10 functional groups of genes with a p
value ranging from 0.002 to 0.018, including “ collagen type IX “, “glycolysis” and
“mitochondrial electron transport, NADH to ubiquinone”, a subclassification of OXPHOS
(Table 6.3).
No significantly differentially expressed genes were found by SAM analysis (censored survival
data) to be related with the prognosis (good [minimal 1-year follow-up, remission or
recurrence] versus poor prognosis [metastasis and/or died of disease]).
Q-PCR
ALDOA, PLOD3, and NDUFB8 and NDUFS3 (involved in OXPHOS) were analyzed by Q-
PCR. Five genes whose RNA were most stably expressed were selected for normalization.
Using GeNorm, we showed that these genes were indeed stably expressed when analyzed
with Q-PCR. Of these five genes, four (CAPNS1, CPSF6, GRP108 and HNRPH1) were
found to be the most stable and were therefore used for normalization. The expression as
detected by Q-PCR showed the same trend as seen in the micro array (Figure 6.2). In case of
PLOD3, a trend of up-regulation with grade was seen, corresponding to the array results (p
= 0.000, Spearman correlation) and for ALDOA, higher expression in the grade II and III
tumors compared to the one grade I was present, although the correlation with the array was
not significant (p = 0.6). NDUFB8 and NDUFS3 demonstrated a trend for down-regulation
with increasing grade, as was also seen with the array data (p = 0.025 and 0.1, respectively,
Spearman correlation; Figure 6.2).
Immunohistochemistry
JUNB immunohistochemistry was performed since a trend for higher expression in Ollier
disease compared with solitary tumors was found. In total, 89 samples were evaluable, 36 of
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which were positive (Ollier disease–related enchondromas 2 of 6, chondrosarcomas 3 of 7;
solitary enchondromas 3 of 21, chondrosarcomas 28 of 55).
cDNA array results were be confirmed by immunohistochemistry evaluating only those
samples used for cDNA array (p = 0.010, Spearman correlation and p = 0.014, T-test, Ollier
disease-related and solitary grade II chondrosarcomas). However, further analysis of the
whole group revealed no difference in expression (p = 1.0, Fisher’s exact test, two-sided).
Interestingly, JUNB expression was significantly lower in non-phalangeal enchondromas [1
of 12 (8%) positive) as compared to non-phalangeal chondrosarcomas (27 of 53 (51%)
positive] (all three grades, p = 0.009, Fisher’s Exact test, two-sided) and also as compared to
chondrosarcomas grade I (10 of 20 (50%) positive) (p = 0.023, Fisher’s Exact test, two-
sided) (Figure 6.3). No significant difference in expression was detected between the different
grades of chondrosarcoma (p = 0.45, chi square, linear by linear).
DISCUSSION
Figure 6.2: Box plots of the relative RNA expression measured by Q-PCR. Relative log10 expression of ALDOA
(A), PLOD3 (B), up-regulated in high-grade tumors and, NDUFB8 (C) and NDUFS3 (D) both downregulated in
high-grade tumors, per subgroup of cartilage, enchondroma of the phalanx (EC-P), chondrosarcoma grade I (CS
I), chondrosarcoma grade II (CS II), and chondrosarcoma grade III (CS III)
79
Expression profiles of central chondrosarcoma
So far, few data are available on the gene expression patterns of conventional central
chondrosarcomas. Expression array analyses have been described [20,27] using arrays
containing genes from libraries other than cartilaginous tissue. We have designed an array
containing 8696 cDNA clones of which ~500 genes are known to be expressed in cartilage.
We previously developed a robust RNA isolation method that enables us to obtain adequate
amounts of RNA from sometimes pauci-cellular cartilaginous tissue to perform cDNA
microarray analysis [20]. Because only limited amounts of RNA can be extracted from benign
and low-grade tumors, due to low cellularity and high amounts of matrix, the hybridization
signal was amplified with Tyramide signal amplification, enabling the use of 1 ìg of total
RNA. Despite these adaptations, sufficient RNA could not be obtained from non-phalangeal
enchondromas, excluding the possibility to investigate gene expression differences related
to malignant transformation of enchondroma to chondrosarcoma.
In a previous cDNA microarray study on commercially available arrays, we compared central
and peripheral chondrosarcoma, revealing, amongst other things, overexpression of ribosomal
genes in central chondrosarcomas and overexpression of immunoglobulins in peripheral
chondrosarcomas [20]. Others, studying a larger group of conventional chondrosarcomas,
showed that these tumors were heterogeneous [27]. Comparing tumors to normal fetal
cartilage, they observed up-regulation of genes related to cell adhesion and motility, both
up- and down-regulation of growth factors, and down-regulation of DNA damage repair and
developmental regulators [27]. To our knowledge, this is the first study relating expression
profiles of central chondrosarcomas to histological grade and Ollier disease.
Comparison of our array data with immunohistochemistry data from this and previous studies
confirmed the quality of our array. JUNB protein expression significantly correlated with
the array results. Cyclin D1 and CDKN1A (p21) immunohistochemistry previously revealed
no difference between the different groups [10], and similar results were obtained using the
arrays. cDNA levels of p53, for which protein expression (and the presence of mutations)
Figure 6.3: JUNB protein expression in enchondromas and central chondrosarcomas. JUNB immunohistochemi-
cal (nuclear) staining demonstrates JunB expression to be absent or very low expressed in enchondromas (A),
with positive internal controls (inset). Chondrosarcomas were positive in about 50% of the cases (B, grade I
chondrosarcoma, with arrow pointing to double nucleus). Original magnification 40x. Color picture can be viewed
at page 130
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was increased in high-grade tumors [11,28], were similar in all grades. This discrepancy can
be explained by the fact that p53 is regulated on protein level, by MDM2 [29,30], and therefore
differential expression on RNA level is not expected. Unfortunately, for genes involved in
the IHH and PTHLH signaling pathways, as well as CDKN2A (p16), for which
immunohistochemical results were reported previously [10,13], no data were available,
because the RNA levels of these signalling molecules are very low in our assay. The
quantitative RT PCR of the present study also confirmed the array data.
We investigated if the same pathways were affected in solitary and Ollier disease-related
tumors. Within the limitations of the small sample size available for this extremely rare
syndrome, the biology of Ollier disease-related tumors could not be distinguished from solitary
tumors, indicating only subtle differences underlie the more indolent clinical behavior [3,4]
and overall higher risk of malignant transformation of Ollier disease-related enchondromas
[1]. To unravel any pathway pointing to the etiology of this rare non-hereditary syndrome,
larger cohorts of patients and more specific knowledge of chondrosarcomagenesis seem
necessary. One of the genes that showed a trend, although not significant, towards higher
expression in Ollier disease was JUNB, a subunit of the AP-1 transcription factor family,
which is implicated in chondrogenic differentiation [31]. JUNB is expressed in normal growth
plates [32] and JunB knockout mice show reduced proliferation of growth plate chondrocytes
and osteoblasts [32]. Up-regulation of JUNB could have explained the more worrisome
histological features in Ollier disease. However, no difference was found between 13 Ollier
Figure 6.4: Summary of the most important results. Enchondromas are characterized by the production of hyaline
cartilage. Upon malignant transformation, the lesion becomes slightly more cellular, with binucleate cells and
sometimes muco-myxoid matrix changes and host bone entrapment. The tumors have little vascularisation. The
present study demonstrates up-regulation of the expression of JUNB in low-grade chondrosarcoma, compared
with enchondroma. The progression of low- to high-grade (grade II and III) chondrosarcoma is marked by in-
creased cellularity, increased nuclear atypia, decreased amounts of extracellular matrix, and increased
vascularisation. Gene expression profiles show changes not only in extracellular matrix, but also in the metabo-
lism of tumor cells. Original magnification 20x
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disease-related and 76 solitary samples, suggesting that JUNB was identified as differentially
expressed by chance because of multiple testing.
Interestingly, the expression of JUNB protein was significantly lower in 12 enchondromas
compared with 20 grade I central chondrosarcomas, which is in line with its stimulatory
effect on chondrocyte proliferation [32,33]. This suggests that JUNB is important in malignant
transformation of enchondroma, making it an excellent candidate as a diagnostic marker for
malignancy (Figure 6.4).
Cartilaginous tumors of the phalanx are considered a separate subgroup since worrisome
histological features are tolerated in phalangeal enchondroma, and phalangeal
chondrosarcoma, being extremely rare at this localization, has a favorable prognosis [1,18].
We have shown the gene expression levels of phalangeal enchondroma to range between
those of grade I and grade II chondrosarcomas located elsewhere. Unfortunately, frozen
material from phalangeal chondrosarcomas was not available for comparison.
To elucidate pathways involved in tumor progression, we compared grade I and grade III
chondrosarcomas. Remarkably, no cell cycle genes were identified in this comparison, as
would be expected based upon the higher mitotic rate of grade III chondrosarcomas compared
with grade I chondrosarcomas. However, we previously found no significant difference in
protein expression between grade I and grade III chondrosarcomas for some of the proteins
involved in the cell cycle, such as cyclin E and cyclin D1 [10], comparable to what is seen in
the array experiment. As could be expected, several matrix-associated genes were down-
regulated in grade III chondrosarcomas. This reflects their histology since high-grade
chondrosarcomas are more cellular, with less matrix with mucoid and/or myxoid appearance
[1,34] (Figure 6.4). In contrast, enchondromas and grade I chondrosarcomas histologically
resemble normal hyaline cartilage, a tissue that lacks blood vessels and is highly hypoxic. In
high-grade chondrosarcomas increased micro-vascularisation is seen [35,36] (Figure 6.4).
In the present study, we have shown up-regulation of glycolysis and down-regulation of
oxidative phosphorylation (OXPHOS) in high-grade chondrosarcomas. Increased glycolysis
is described in several cancer types [37,38], and even suggested to be a hallmark of invasive
tumors [39]. The up-regulation of anaerobic glycolysis in the hypoxic (ie low-grade) situation
is hypothesized to give a growth advantage [39]. With increased vascularisation (ie high-
grade), more oxygen is available to the cells and the use of the glycolytic pathway is not
down-regulated, but most likely changed from anaerobic to aerobic [39]. The down-regulation
of the OXPHOS may result from the increased glycolysis and can be reversed in some cases
[40]. Other explanations for the up-regulation of glycolysis and down-regulation of the
OXPHOS could be the need for products produced in the glycolysis, the inability to store
glucose in the cancer cells, failure of the OXPHOS complex, or to decrease the amount of
reactive oxygen species that are can induce DNA damage. Hif-1α (hypoxia-inducible factor
1α) could be important in chondrosarcoma progression since it can induce both up-regulation
of glycolysis [37] and vascular in-growth. However, conflicting results are reported regarding
the up- and down-regulation of this protein in chondrosarcomas [41,42] and no data could be
retrieved from our array. As a consequence of glycolysis, lactate is formed, resulting in
microenvironmental acidosis being toxic to cells, resulting in necrosis or apoptosis through
82
Chapter 6
p53- and caspase-3-dependent mechanisms [43,44]. In chondrosarcomas, the anti-apoptotic
protein BCL2 is up-regulated [9,10], which may be required to escape the acidosis-induced
apoptosis.
In conclusion, we have shown that chondrosarcomas from patients with Ollier disease and
solitary chondrosarcomas display similar gene expression profiles, suggesting that the same
pathways are involved in histogenesis. JUNB was expressed significantly more highly in
chondrosarcomas than in enchondromas, suggesting it to be a good diagnostic marker for
malignancy. Progression of chondrosarcomas towards a higher grade is accompanied by up-
regulation of glycolysis and down-regulation of oxidative phosphorylation genes suggesting
that adaptation to the energy supply of tumor cells is related to chondrosarcoma progression.
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Array-CGH of central chondrosarcoma: identification of RPS6 and CDK4 as
candidate target genes for genomic aberrations
LB Rozeman, K Szuhai, C Rosenberg, HJ Tanke, AHM Taminiau, AM Cleton-Jansen,
JVMG Bovée, PCW Hogendoorn
Submitted
Enchondromas are benign lesions, which can occur solitary or multiple (Ollier disease) and
could be precursors of central chondrosarcomas. Recurrences of chondrosarcoma can be of
higher grade compared to the primary tumor, suggesting possible progression. Tumor specific
genomic abnormalities are unknown so far. Genome-wide array-CGH (comparative genomic
hybridization) was used to investigate copy number changes in enchondromas and central
chondrosarcomas to elucidate both primary genetic events, and those related to tumor
progression. ANOVA, T-test and hierarchical clustering were used for analysis. Array-CGH
data were compared to cDNA expression array data. No genomic imbalances specific for
Ollier disease were found. Genomic imbalances were rare in enchondromas and grade I
chondrosarcomas, while frequently in high-grade tumors. We identified 22 chromosome
regions, imbalanced in ≥ 25% of tumors, three of which located on chromosome 12 (12p13,
12p11.21-p11.23 and 12q13, containing amongst other the gene PPFIBP1 [PTPRF interacting
protein, binding protein 1]). Loss of chromosome 6 and gain of 12q12 were associated with
higher grade. Loss of 4q13, 4q34, 10 and gain of 9q34 correlated with adverse prognosis,
and higher grade. Comparison of array-CGH with cDNA expression showed correlation for
RPS6 (ribosomal protein S6) and CDK4 (cyclin-dependent kinase 4). We identified genomic
regions and new candidate genes (RPS6, CDK4 and PPFIBP1) associated with tumor
progression and prognosis in high-grade chondrosarcomas.
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Chondrosarcoma of bone is a slowly growing malignant tumor characterized by the formation
of cartilage. The tumors have an equal sex incidence and principally occur in adults of 30–60
years. Chondrosarcomas are found most frequently in the long bones (33%), pelvic bones
(27%), and in ribs and scapula (10%). The majority of chondrosarcomas (~83%) arise centrally
within the medullary cavity of bone and are called primary conventional central
chondrosarcomas, or secondary central chondrosarcomas if they develop from a pre-existing
enchondroma [1]. The latter can be solitary or multiple in the context of Ollier disease
(enchondromatosis). A minority (~17%) of chondrosarcomas are subclassified as secondary
peripheral, developing at the surface of bone within the cartilaginous cap of a documented
pre-existing osteochondroma [2,3]. Conventional central and secondary peripheral
chondrosarcoma share similar cytonuclear features and three grades of malignancy are
discerned [4], correlating with the occurrence of metastases and survival [1]. However, there
is clear evidence for genetic differences between central and peripheral chondrosarcoma
[5,6].
In few publications only the distinction between central and secondary peripheral
chondrosarcomas is made. As shown by DNA flow cytometry central chondrosarcomas are
predominantly near-diploid [6], whereas peripheral chondrosarcomas are aneuploid [5-8].
Loss of heterozygosity (LOH), classic CGH and karyotyping show a broad range of
presumably mostly random genomic alterations in high grade cases with some indications
that chromosome 9 is more often affected [6,8-10].
Cytogenetic data of studies in which no distinction was made between central and peripheral
chondrosarcomas revealed several aberrations in recurrent chromosomal regions (reviewed
by Sandberg and Bridge [10]) of which some, e.g. the loss of 13q, were reported to have a
prognostic impact [11]. Enchondromas show mainly a normal karyotype [10,12].
Several genes, such as TP53 and CDKN2A/p16, have been tested in central chondrosarcomas
for the presence of mutations. The TP53 gene on chromosome 17p13 was found to be deleted
or mutated in some chondrosarcomas, mainly in high-grade tumors [13-17]. CDKN2A, located
on chromosome 9p21, has been studied extensively in central chondrosarcomas. Although
cytogenetics, CGH and LOH point to the 9p21 region as an important candidate locus for
central chondrosarcoma development [6,8,9], mutations and methylation (a mechanism of
gene downregulation) of the CDKN2A gene combined with absent p16 protein expression is
found in only a subset of mainly high grade central chondrosarcomas [18-20].
For enchondromas in the context of Ollier disease the overall percentage of malignant
transformation is much higher. It has been estimated at 25-30% per patient with Ollier disease
compared to less than 1% for patients with solitary enchondromas [1,21]. Genetic data on
patients with Ollier disease are sparse. LOH was identified at 13q14 and 9p21 [22], whereas
cytogenetic studies revealed no [8] or only one alteration per tumor, i.e., either deletion of 1p
[23] or an inversion on chromosome 9 [8]. A mutation in 2 out of 6 patients with Ollier
disease was reported in the PTHR1 gene [24], although another study on 31 patients with
Ollier disease could not confirm this [25].
In order to further identify genomic alterations we performed a genome wide screen by high-
resolution array-CGH on solitary and Ollier disease-related enchondromas and conventional
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central chondrosarcomas. We looked for genomic alterations, specific for central
chondrosarcoma and Ollier disease, and those related with tumor progression and prognosis.
The results were compared to expression array data. Tumors from patients with Ollier disease
were included to identify putative genetic changes specific for this syndrome.
MATERIAL AND METHODS
Samples
Fresh frozen enchondroma and conventional central chondrosarcoma samples were collected
from the archives of the department of Pathology of Leiden University Medical Center. All
samples were either primary conventional chondrosarcoma, or secondary to a radiological
longstanding documented enchondroma. No samples originating from recurrent tumors were
used. In total, 21 tumor samples (three enchondromas, seven grade I, seven grade II and four
grade III chondrosarcomas) were used (Table 7.1). One of these patients was previously
diagnosed with a breast carcinoma [26]. Patient data were obtained by review of clinical
charts and radiographs. All but one patients were operated by one othopaedic oncologist
(A.H.M.T.). Grading was performed according to Evans et al. [4]. All samples were handled
in a coded fashion and all procedures were performed according to the ethical guidelines
“Code for Proper Secondary Use of Human Tissue in The Netherlands” (Dutch Federation
of Medical Scientific Societies).
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DNA isolation
For DNA isolation, we used samples containing at least 70% of tumor cells, as estimated
from analyses of haematoxylin and eosin stained frozen sections. Four samples were
microdissected to enrich the tumor percentage [5]. The DNA was isolated using a Wizard
genomic DNA purification kit (Promega Benelux, Leiden, The Netherlands), according to
the manufacturer instructions. The concentration of the DNA was quantified
spectrophotometrically and the DNA fragment sizes were determined on a 0.7% agarose gel.
Our samples were hybridized against a sex-matched control DNA pool created from >10
normal blood DNAs (Promega).
Array-CGH
The 1 Mb resolution arrays were constructed using a BAC/PAC clone set provided by the
Welcome Trust Sanger Institute (UK), and information regarding the full set is available at
the Sanger Center mapping database site, Ensembl (http://www.ensembl.org/). The array
production, hybridization and image acquisition procedures were performed as previously
described by us [27].  In short, all samples were labeled with Cy3-dCTPs and hybridized on
a the slides together with Cy5-dCTPs labeled reference DNA. Hybridized slides were scanned
with an Agilent DNA microarray scanner.
Data analysis
Spot intensities were measured by GenePix Pro 4.1 software. Those that did not fulfill quality
criteria were excluded, namely: spots with low intensity (below five times the average of the
background), or non-similar values among replicates [27]. Further analysis and averaging of
the triplicate spotted clones was performed using home made Excel algorithms [27] and
CGH Analyzer MeV (University of Pennsylvania, Abramson Cancer Research Institute, Weber
Lab)[28]. The determination of significant copy number changes detected in array-CGH for
tumor samples, where a substantial part of the genome is altered, is not straightforward. The
identification of breakpoints and the determination of the true copy number values is
problematic due to aneuploidy and admixture of non-tumor cells. To facilitate and standardize
the data analysis aCGH-Smooth was used [29]. Clones that showed imbalances also in normal
controls were considered polymorphic [30], and were excluded from further analysis.
FISH (Fluorescent In Situ Hybridization)
Interphase FISH was performed to confirm the imbalance in tumor, and exclude its presence
in the constitutive line of this patient. Nuclei from paraffin embedded normal and tumor
tissue were isolated from sample L803 as described previously [31]. Three probes were
selected, two located within the amplified region, and one immediately adjacent to this region.
The DNA used as probes in the FISH experiments represented aliquots of the same amplified
DNA used to spot the arrays. DNAs were directly labeled by nick translation with
fluorochrome conjugated d-UTPs, and hybridized according to standard protocols.
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Correlation of genomic alterations and expression levels
Expression array data were available for 13 of the 21 tumors studied [32]. RNA from these
tumors was hybridized to a cDNA array containing 8696 cDNA clones, representing common
genes and a selection of genes (~500) known to be expressed in cartilage, growth plate or
involved in carcinogenesis in general. Most of these genes were selected from the human
ResGen 40K bank (Research Genetics, Invitrogen, Huntsville, AL, USA), others were or-
dered from DKFZ (RZPD, Berlin, Germany) or custom made. The clones were printed in
duplicate on Micromax SuperChip glass slides (Perkin Elmer, Wellesley, MA, USA) and 1
mg of total RNA from the samples was labeled with biotin and one mg of reference panel total
RNA was labeled with fluorescein generating biotin and fluorescein labeled cDNAs with the
Micromax TSA labeling kit (Perkin Elmer, Wellesley, MA, USA) according to the supplied
protocol.
Of the SRO’s (smallest region of overlap), array GCH and cDNA-array data were compared,
to relate gene expression effects to DNA copy number alterations.
RESULTS
Array-CGH
After hybridization to the BAC arrays, 95-99% of the spots fulfill the quality criteria [27]
and were used in the analysis. In 10 cases with statistically significant copy number alterations
the samples showed with high normal cell contamination, as was reported previously [6],
despite the efforts to enrich the tumor percentage by micro dissection in some cases. In these
cases extra adjustments (aCGH-Smooth) were applied to be able to input data to MeV software
package (samples L761, L1212, L172, L654, L813, L861, L908, L795, L903, and L1066).
Genomic alterations were mainly found in the high-grade samples. No DNA copy number
alterations were found in the samples 2-6 and 8 (two enchondromas and four grade I
chondrosarcomas). Overall, grade III chondrosarcomas showed the largest number of DNA
imbalances (enchondromas average 8 imbalances, range 4-11; grade I chondrosarcomas
average 18 imbalances, range 3-26; grade II chondrosarcomas average 28 imbalances, range
9-39; and grade III chondrosarcomas average 43 imbalances, range 26-74) (Figure 7.1).
DNA copy number alterations that show an overlapping region present in at least five different
samples (smallest region of overlap [SRO]) and comprising at least 3 adjacent clones, are
given in Table 7.2.
Analysis of genomic alterations in Ollier disease-related tumors
In order to identify possible Ollier disease specific alterations, we looked at the alterations
found in the four samples with Ollier disease (2 phalangeal enchondromas and 2 grade II
chondrosarcomas). Of the 2 phalangeal enchondromas one revealed no alterations, whereas
the other sample showed loss of complete chromosome 6. Two grade II chondrosarcomas
showed more alterations, of which one showed gain of almost the entire chromosomes 2, 5,
8, 15, 19, 20, 21 and 22 and gain of parts of the chromosomes 1, 5, 7, 9, 16, 17 and 18. The
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second Ollier disease-related grade II chondrosarcoma contained both losses (on chromosomes
1, 3, 4, 6, 9, 10, 13, 15, 16, 22) and amplifications (on chromosomes 6, 7, 12, 14, 15, 16, 17,
18, 19). None of the alterations recurred in all four, or even three of the four samples, nor
were any of the changes specific for Ollier disease (i.e. absent in solitary tumors).
Correlation with grade
Clear differences were found in the number of aberrations between low- and high-grade
tumors. To investigate whether some of these alterations specifically correlated with
histological grade, ANOVA and T-test analyses were performed. No clear distinctions between
the grades were seen, when all grades were taken in account. By comparing only grade II to
grade III chondrosarcomas we found that gain of four clones on chromosome 12 (p <  0.001),
of which three are adjacent on chromosomal region 12q12 (~1.3 Mb), was significantly
Figure 7.1: Genomic alterations found in enchondromas and conventional central chondrosarcomas. The ideo-
gram shows the distribution of the numerical aberrations subdivided in enchondroma and the three different grades
of chondrosarcoma. Gains are shown on the right, losses on the left. Gain of chromosomal region 12q12 is asso-
ciated with grade III chondrosarcomas. Loss of chromosomes 10, 4q13, 4q34.3 and gain of 9q34 are associated
with adverse prognosis. * marks the location of 4q13, 4q34.3, 9q34 and 12q12
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more frequent in grade III chondrosarcomas (Figure 7.2). This region contains amongst others
HDAC7a (histon deacetylase 7A) and SENP1 (SUMO1/sentrin specific protease1).
Previously it was  reported that loss of 6q is associated with impaired metastasis-free survival
[11]. Hierarchical clustering of the samples with solely clones from chromosome 6 partly
separated the grade III chondrosarcomas from the other tumor grades (p < 0.05, Figure
7.3a). Hierarchical clustering of clones from chromosome 10 showed separate clusters for 6
tumors with recurrence, metastasis and/or dead of disease (p < 0.05, not shown). Hierarchical
clustering on other previously reported chromosomal areas (i.e. of chromosome 11, 13, 22,
Figure 7.2: Hierarchical clustering of the four clones of chromosome 12 differentiating between grade II and
grade III chondrosarcomas. Two clusters, one containing mainly grade III (amplified) samples and the other one
containing grade II chondrosarcomas, can be discerned. Color picture can be viewed at page 130
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as reported by Mandahl et al [11] revealed no separate cluster formation of grade and/or
outcome.
Correlation with prognosis
To identify possible regions associated with adverse prognosis we compared cases with no
evidence of disease to those with recurrence (excluding tumors with a positive surgical
margin), metastasis and/or dead of disease, and for which the follow up was minimal 1 year,
except if an event had occurred within the first year. T-test identified 165 BAC clones (p <
0.001) that showed differences between the two groups and hierarchical clustering with these
clones identified a near perfect distinction (Figure 7.3b), correlating with histological grade.
Of these BACs 95 were located on chromosome 10 (almost all consecutive on 10pter -
10q25.3). Two consecutive regions were present on chromosome 4, ~4.2 Mb on 4q13 and
~4.4 Mb on 4q34.3, lost in 3 grade III chondrosarcomas with recurrence (L171), metastasis
and recurrence (L1066) and dead of disease (L795). One continuous region was identified
on chromosome 9, ~6.2 Mb on 9q34.
Correlation of genomic alterations and expression levels
Figure 7.3: Hierarchical clustering of the tumors. A) hierarchical clustering on the clones of chromosome 6. A
distinct cluster containing all grade III chondrosarcomas, one grade I chondrosarcoma and one enchondroma is
evident, separating the grade III chondrosarcomas from almost all other grades. B) Hierarchical clustering on the
131 BAC clones, as found by T-test for prognosis shows the clustered distribution of the samples with no evidence
of disease as compared to those with recurrences, metastasis or dead of disease. (Abbreviations: III: grade III
chondrosarcoma; II: grade II chondrosarcoma; I: grade I chondrosarcoma; E: enchondroma; FU: follow up;
rec.: recurrence; ?: lost to follow up; meta.: metastasis; dod: died of disease)
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We subsequently analyzed gene expression profiles of the SRO’s identified by array-CGH
(Table 7.2) for 13 tumors (see Table 7.1) of which expression array data were available [32].
Gene expression of tumors with loss/gain in the SRO was compared to gene expression of
tumors without the loss/gain (Table 7.2). Overall the genomic alterations did not result in a
significant alteration of the gene expression levels. However, expression of two of the
aproximately 300 in this experiment tested genes, CDK4 (12q13) and RPS6 (9p21-24),
appeared to correlate (p = 0.000 and 0.004 Pearson’s R, respectively) with the genomic
alteration (Figure 7.4).
FISH
Tumor L803 showed a normal profile, except for a copy number gain of three adjacent
clones on chromosome 4q32 (RP11-218F10, RP11-336N6 and RP11-25N12). Interphase
FISH analysis was performed to confirm that the amplification of the region is related to the
tumor, and to exclude the possibility of a germline amplification, using two of the amplified
clones and one adjacent non-amplified clone. The amplification was confirmed in tumor
cells and was absent in non-tumor cells of the patient (data not shown).
DISCUSSION
We used array-GCH to examine if DNA imbalances were present in solitary and Ollier disease-
related enchondromas and conventional central chondrosarcomas. It has already been
demonstrated in osteosarcoma [33] and other tumor types that array-CGH may uncover
previously undetected DNA copy number changes [34], and can be used to indicate
chromosome regions containing genes involved in tumor origin and progression. This study
represents the first application of genome-wide copy number screening by array-GCH in
chondrosarcomas.
Figure 7.4: Correlation RNA expression with amplification/deletion found by array-CGH. A) CDK4 [p = 0.000,
Pearson’s R], B) RPS6 [p = 0.004, Pearson’s R]
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Our array GCH results are in agreement with genomic changes previously reported at the
cytogenetic level (4-10Mb resolution) by G-banding and chromosome CGH [9,10,35], with
absent or a limited number of alterations in enchondromas and the presence of several genomic
alterations in chondrosarcomas (such as deletion of 9p, gain of parts of chromosome 12 and
gain of chromosome 20 and 21; Figure 7.1). The number of changes is increased in tumors
with higher grade.
The genetic changes that underlie the origin of Ollier disease, and distinguish its behavior
from solitary tumors, are still unclear [1,21]. We compared the tumors from patients with
Ollier disease with each other and to the solitary tumors. No genomic alteration was found to
be present in all, or exclusively, in Ollier disease samples. Also at expression level, our
cDNA array analysis did not reveal differences between Ollier disease-related and solitary
enchondromas and chondrosarcomas [32]. However, we cannot exclude that more subtle
changes could underlie this syndrome, such as amplifications/deletions smaller than ~1 Mb,
or balanced rearrangements, which cannot be identified with array-CGH. However, balanced
rearrangements have not been reported in Ollier disease-related tumors or conventional central
chondrosarcomas [8,10,12,23]. Another possibility is that Ollier disease is caused by point
mutation of a gene. The suggested role of PTHR1 was excluded by us [25].
Our study revealed that gains and losses of large DNA segments (>1 Mb) are not present in
all tumors, and 2 out of 3 enchondromas and 4 out of 7 grade I chondrosarcomas exhibited
no detectable alterations in DNA copy numbers. High numbers of alterations mainly including
large DNA segments (arms/whole chromosomes) were present predominantly in the high-
grade tumors. These alterations can be both recurrent and random, the latter presumably
representing chromosomal instability. Applying a cut-off of minimally present in five samples
we identified 22 smallest regions of overlap (Table 7.2), ranging from 0.55-113 Mb.
One SRO involved a deletion of 9p21.3-p24.1. This region has been reported to be deleted in
chondrosarcomas before [10], and contains the locus INK4A/INK4A-ARF, coding for the
tumor suppressor genes CDKN2A/CDKN2C. Previously we [20] and others [18] have
investigated this locus, and found that loss of this locus or the protein was associated with
high histological grade. However, we identified another gene involved in the 9p deletion,
RPS6 (ribosomal protein S6), of which low expression levels significantly correlated with
the deletion. This protein belongs to the S6E family of ribosomal proteins, regulated by
phosphorylation. The protein may contribute to the control of cell growth and proliferation
through the selective translation of particular classes of mRNA [36], and is therefore a
candidate tumor suppressor gene in chondrosarcomas.
Chromosome 1 contained two SRO’s that were deleted, 1p36.22-p36.31 and 1p13.2-p22.1
[also reported previously [10]]. The region 1p13.2-p22.1 contains amongst others EXTL2. In
patients with multiple osteochondromas, a hereditary syndrome with multiple exostoses that
may transform into secondary peripheral chondrosarcomas, two other members of this gene
family are involved [37]. These patients have mutations in the EXT1 or EXT2 genes that
encode for proteins involved in the heparan sulphate side chain elongation. EXTL2 is
homologous to EXT1 and 2, and initiates the heparan sulphate synthesis [38]. Since
conventional central chondrosarcomas histologically resemble the secondary peripheral
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chondrosarcomas, EXTL2 could be a target for deletion. However, cDNA microarray analysis
revealed no difference in RNA expression of EXTL2 between the tumors that contained a
deletion of this SRO and those without this deletion.
Chromosome 12 contained three SRO’s. Chromosomal region 12q13 was found gained in 6
tumors (2 grade I, 1 grade II and 3 grade III chondrosarcomas). This region has been reported
previously in chondrosarcomas and other sarcomas [10,39]. Several genes in this region
have been indicated to be of importance for tumorigenesis. For instance SAS (sarcoma
amplified sequence), CDK4 (cyclin dependent kinase 4), and GLI (glioma-associated oncogene
homologue) are located in the amplified zone. Two other often implicated genes in sarcomas,
HMGA2 (high mobility group AT-hook 2) and MDM2, are located just outside the region we
found. cDNA microarray analysis revealed a higher expression of CDK4 in tumors in which
this region was amplified (Figure 7.4), also reported for other tumors [40]. Expression profiles
of other genes in this region were not correlating with the genomic gain. However, further
studies are required to confirm these findings in other tumor samples.
Chromosomal region 12p11.21-p11.23 was gained in 5 tumors (2 grade I, 1 grade II and 2
grade III chondrosarcomas). One of the genes in this region is PTHLH (parathyroid Hormone
like hormone), which is an important gene for chondrocyte growth and differentiation.
Previously we reported that this protein is expressed in almost all enchondromas and
chondrosarcomas [41,42]. This region also contains PPFIBP1 (PTPRF interacting protein,
binding protein 1), which was found to interact with S100A4, a calcium-binding protein
related to tumor invasiveness and metastasis [43]. For these genes no data were available in
the cDNA microarray experiment.
Genomic gain of the oncogenes JUNB and JUND, located in the SRO 19p13.11-p13.3 was
seen in 7 tumors. We previously found that JUNB protein expression was found to be
upregulated in chondrosarcomas compared to enchondromas [32]. Both JUNB and JUND
are proto-oncogenes, overexpressed in several cancer types [44,45] and are transcription
factors influencing the cell cycle regulation [46]. cDNA expression analysis revealed
expression of both JUNB and JUND in almost all tumors, at similar levels regardless of
amplification of the SRO 19p13.11-p13.3.
In general, most alterations were found only in high-grade tumors. Analysis of the different
grades identified 2 regions capable of partly separating the different grades. Copy number
gain of region 12q12 separated grade II from grade III chondrosarcomas in hierarchical
clustering (Figure 7.2). This region (~1.3 Mb) contains amongst others HDAC7a (histone
deacetylase 7A) and SENP1 (SUMO1/sentrin specific protease1). SENP1 is capable of
reducing the deacetylase activity of HDAC1 (histone deacetylase 1) [47] and therefore both
are involved in histone activity. Also chromosome 6 contains several histone genes (deleted
SRO, 6p22-p21.3), and hierarchical clustering of the clones on this chromosome also partly
separated the grade III chondrosarcomas from the others (Figure 7.3). Two other regions
containing a cluster of histone genes, 1q21 and 1q42, were not affected. Histones are involved
in the packaging of the genome, protecting it from damage, and regulation of gene expression
by making the gene (in)accessible for transcription [48]. The SRO 6p21 en SRO 12 may
therefore affect the genome stability resulting in damage of DNA.
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Investigating a potential correlation with prognosis revealed that tumors with loss of
chromosome 4 (4q13 and 4q34) and 10 and gain of 9 (9q34) may have a bad prognosis.
These aberrations also correlate with increase in histological grade and tumor size. Cluster
analysis of all tumors used in this article of clones from chromosome 10 did not result in
such a clear separation, as was the case for the cluster analysis of those on the tumors used
for association with prognosis. However, the here found prognostic gains and losses should
be tested further on a separate group of tumors, to proof their validity. In cluster analysis one
tumor performed somewhat unexpected, clustering together with the tumors with adverse
prognosis while no recurrence or metastasis has been reported in this patient. However,
follow up for this patient has only been available for 16 months, which is relatively short for
chondrosarcomas [49], since recurrences may still occur within five years after surgery and
metastases after 10.
In conclusion, recurrent alterations (SRO’s) were found in chondrosarcomas, as well as non-
specific genomic instability, predominantly in high-grade chondrosarcomas. These alterations
involve chromosome 12, of which multiple regions are amplified (three SRO’s: 12p13,
12p11.21-p11.23, 12q13 and one related with prognosis: 12q12) and chromosome 6. We
therefore hypothesize that these parts of the chromosome play an important role in the tumor
progression of chondrosarcoma. The expression of CDK4 correlated with the genomic
alteration on 12q13. For the well-known loss of chromosomal region 9p21, we introduce
RPS6 as a possible other gene of interest, in addition to CDKN2A.
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I. Expression analysis of central chondrosarcoma
The mechanism behind malignant transformation of enchondromas into chondrosarcomas is
not known, and as yet no molecular markers have been identified for the difficult histological
differential diagnosis of enchondroma versus low-grade central chondrosarcoma. The
histological grading system of the chondrosarcomas is hampered by interobserver variations
in evaluation of the different histological features. Chondrosarcomas are one of the rare
mesenchymal tumors that upon recurrence may show progression in grade. Thus investigation
of the expression patterns characterizing different grades may give an insight in the
mechanisms of this process and may also shed light on genetic pathways involved in metastasis
and disease-related death.
I.a. Specific (hypothesis driven) expression analysis
RNA and protein expression was investigated in the chapters 3 (CDKN2A), chapter 5
(IHH and PTHLH signaling) and chapter 6 (JUNB).
I.a.i. CDKN2A
The gene coding for the p16 protein is located in a region that is deleted in a subset of central
chondrosarcomas. Combined analysis of genetics and protein expression revealed loss of
this genomic region and loss of protein expression in mainly high-grade chondrosarcomas
(chapter 3). However, there was no correlation between loss of protein expression, LOH
and or promotor methylation, suggesting an alternative manner of downregulation of gene
expression.
I.a.ii. JUNB
JUNB was one of the genes that showed a small, but non-significant, difference comparing
three Ollier disease-related grade II chondrosarcomas with four solitary grade II
chondrosarcomas using a large scale gene expression analysis (chapter 6). This protein is a
subunit of the AP-1 transcription factor family, and is implicated in chondrogenic
differentiation. JunB knock-out mice show reduced proliferation of growth plate chondrocytes
and osteoblasts. Comparing the protein expression of this gene in a larger group of Ollier
disease-related and solitary enchondromas and central chondrosarcomas revealed that no
difference was present between these two groups. However, comparing enchondromas and
low-grade chondrosarcomas, a significant increase of protein expression was found in
chondrosarcomas, suggesting the possible use of JUNB as a diagnostic marker in the
distinction between enchondromas and low-grade chondrosarcomas.
I.a.iii. IHH and PTHLH signaling
In chapter 1 and 2 it was discussed that the IHH/PTHLH signaling plays an important role
in the growth and differentiation of the normal growth plate. In hereditary osteochondromas
these signaling pathways are affected by mutations in the EXT1 or EXT2 gene. The expression
of molecules involved in the IHH/PTHLH signaling in enchondromas and central
chondrosarcomas was investigated in chapter 5.
105
Summary and conclusion
Proteins of both signaling pathways were studied by immunohistochemical analysis (PTHLH
signaling: PTHLH, PTHR1, BCL2, p21, cyclin D1 and cyclin E) or RNA expression (IHH
signaling: IHH, PTCH, SMOH and GLI2). The data show that IHH signaling is absent in
enchondromas and central chondrosarcomas, while PTHLH signaling is active. There was
no difference in expression of any of the molecules between 35 enchondromas and 26 grade
I central chondrosarcomas, indicating that PTHLH signaling is not important in malignant
transformation of enchondroma. Higher expression of PTHR1 and BCL2 at the
immunohistochemical level was associated with increasing histological grade in
chondrosarcoma, suggesting involvement in tumor progression.
I.b. Large scale gene expression analysis
In chapter 6 RNA expression levels of enchondromas and central chondrosarcomas was
studied genome wide, by cDNA micro array analysis. Possible changes underlying malignant
transformation could not be investigated, due to the fact that RNA isolation of non-phalangeal
enchondromas did not yield enough RNA for expression studies. Expression patterns related
to progression were investigated by comparing grade I and grade III central chondrosarcomas.
Apart from already known/suspected alterations, such as downregulation of extracellular
matrix genes, other processes were significantly different between these two groups.
One of these was downregulation of the oxidative phosphorylation, and upregulation of the
glycolysis in grade III chondrosarcomas. Both processes are involved in the energy supply
of the cell. Increased glycolysis is described in several cancer types, and even suggested to
be a hallmark of invasive tumors. The upregulation of anaerobic glycolysis in the hypoxic
(i.e. low-grade) situation is hypothesized to give a growth advantage. With increased
vascularization (i.e. high-grade), more oxygen is available to the cells and the use of the
glycolytic pathway is not downregulated, but most likely changed from anaerobic to aerobic.
The downregulation of the OXPHOS may result from the increased glycolysis and can be
reversed in some cases. Other explanations for the upregulation of glycolysis and
downregulation of the OXPHOS could be the need for products produced in the glycolysis,
the inability to store glucose in the cancer cells, failure of the OXPHOS complex, or to
decrease the amount of Reactive Oxygen Species, that are capable to induce DNA damage.
II. Genetic aberrations of central chondrosarcoma
So far few specific genomic alterations have been found specific for enchondromas and
conventional central chondrosarcomas (9p21, 12q). In previous studies often both conventional
central and secondary peripheral chondrosarcomas were analyzed as one group, obscuring
possible specific aberrations in either subgroup.
In chapter 3, based on previous studies, the location of loss on 9p21, which seems to be
specific for central chondrosarcomas was investigated further. In this area one of the genes
was the tumor suppressor CDKN2A, which is involved in cell cycle regulation and is a target
for deletion in many other types of cancers. Loss of heterozygosity (LOH ) of four markers,
surrounding the CDKN2A/INK4a locus, was found in 15 out of 39 chondrosarcomas (38%).
Screening for mutations in the genes CDKN2A and p14ARF, by SSCP analysis, did not reveal
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any mutations in 47 cases in either gene. Our results suggest that a locus other than the
CDKN2A/INK4a must be the target of LOH at 9p21.
In chapter 7 we investigated genome wide, using array-CGH, the genomic aberrations in 21
primary tumor samples, three enchondromas, seven grade I, seven grade II and four grade III
chondrosarcomas. We observed an increase in the number and size of the aberrations,
correlating with increased histological grade. In case of enchondromas (of the phalanx) and
grade I chondrosarcomas generally the number of aberrations was limited and the size of the
amplifications/deletions was small, although for instance in one enchondroma loss of complete
chromosome 6 was observed. In the high-grade tumors substantially more alterations were
observed, often in a seeming random manor, as if genomic instability is taking place.
None of the alterations were present in all tumors, but recurrent alterations were observed.
By applying a cut-off of minimally affected in 5 or more tumors in the same manor (all lost,
or all gained) and a minimum of 3 adjacent clones, we identified 22 regions, ranging from
0.55 till 113 Mb. Some of these regions were reported previously, while others were not.
Interestingly, some chromosomes contained multiple regions, like chromosomes 7 (7p12.3-
p15.3, 7p11.2-q11.23, 7q36.1-q36.3), 12 (12p13, 12p11.21-p11.23 and 12q13) and 20
(20q11.21, 20q12, 20q13.33). Analysis of the data revealed that some chromosomes and
regions seemed specific for either progression and/or prognosis. Loss of chromosomes 6, 10
and gain of 12q12 was correlated with increasing grade and loss of chromosome 10 (10pter
- 10q25.3), 4q13, 4q34.3 and gain of 9q34 was correlated with adverse prognosis.
In general, amplifications of chromosome 12 are reported frequently in tumors. Especially
in several sarcoma types, such as osteosarcomas and liposarcomas, amplification of 12q13-
15 is a frequent finding. This region contains amongst others the genes CDK4, MDM2, SAS
and genes coding for high mobility group (HMG) proteins. Amplification of the short arm of
chromosome 12 is seen in other cancer types, such as testicular germ-cell tumors, distal bile
duct carcinoma and pancreatic carcinoma. In both testicular germ-cell tumors and pancreatic
carcinomas specifically the region 12p11 is also implicated. Gain of 12p is thought to be
related to malignant progression.
Combining the results from the cDNA expression array (chapter 6) and array-CGH (chapter
7), the RNA expression levels of genes located in the recurrent regions of amplification or
deletion were analyzed (chapter 7). We found that for two genes on our cDNA array the
expression matched the changes seen in the BAC array. CDK4, located on 12q13, was higher
expressed in tumors containing an amplification of this region. Of the second gene, RPS6
(ribosomal protein S6), located in the deleted region 9p21.3-p24.1, low expression levels
significantly correlated with the deletion. These data suggest that the mentioned genes may
be the targets for the amplification and deletion found.
III. Multi-step model for tumorigenesis
Combining all data, a multi step model for the development of central cartilaginous tumors
can be proposed (Figure 8.1).
With the malignant transformation of enchondroma towards chondrosarcoma upregulation
of the protein JUNB is observed (chapter 6). The progression of low- to high-grade
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chondrosarcomas shows the upregulation of the glycolysis, combined with the downregulation
of the oxidative phosphorylation (chapter 6). Increased protein expression of PTHR1 and
BCL2 is also observed with increasing histological grade (chapter 5), whereas the protein
expression of p16 decreases (chapter 3). On the genomic level, no specific alterations were
observed in enchondromas and low-grade central chondrosarcomas. The transition of low-
to high-grade central chondrosarcomas is characterized by loss of chromosome 6, 10 and
gain of chromosomal region 12q12, although loss of chromosome 6 was also observed in
one enchondroma. In addition, the number of losses and gains as well as the size of these
aberrations increased in high-grade tumors, possibly as a result of genomic instability (chapter
7). Correlating with adverse outcome are the loss of 4q13, 4q34, and 10pter-10q25 and gain
of 9q34 (chapter 7).
IV. Conventional central chondrosarcoma subtyping
Within the conventional type of central chondrosarcomas, based upon clinical data, different
subtypes can be distinguished. Chondrosarcomas located in the phalanx display a more
indolent clinical behavior compared to those with similar histological features located in
other regions of the skeleton. Also in patients with enchondromatosis, characterized by
multiple central cartilaginous lesions, criteria are different, as a consequence of the different
clinical features, compared to those of solitary tumors.
IV.a. Phalangeal lesions
In chapters 5 and 6, RNA and protein expression levels of tumors located in the phalanx
were compared to enchondromas and chondrosarcomas located elsewhere to elucidate whether
these tumors are biologically different from those located at other regions, or whether the
location is causative for their good prognosis.
For immunohistochemical analysis (chapter 5) the chondrosarcomas located in the phalanx
were compared to chondrosarcomas grade II located elsewhere, based upon similarities in
their histology. In total for 64 enchondromas (21 located in phalanx) and 89 chondrosarcomas
Figure 8.1: Multi-step model for the development of central cartilaginous tumors. A question mark is placed since
the origin of enchondromas and chondrosarcomas is not known, and it has been debated whether they arise from
pluripotent mesenchymal stem cells or from cartilage rests from the growth plate that have not undergone calcifi-
cation
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(17 located in phalanx) the IHH and PTHLH signaling was investigated. Overall statistical
analysis revealed no significant differences between chondrosarcomas located in the phalanx
and chondrosarcoma grade II located elsewhere in the skeleton. However, a small subset of
phalangeal chondrosarcomas demonstrated downregulation of PTHLH.
RNA expression analysis, by cDNA microarray analysis (chapter 6), was performed on
three phalangeal enchondromas and 19 chondrosarcomas elsewhere of different grades.
Overall the expression levels of the phalangeal enchondromas were found to be intermediate
to those of grade I and III chondrosarcomas. Moreover, the immunohistochemical comparison
of phalangeal enchondromas with enchondromas located elsewhere revealed increased
expression of BCL2 and a trend for increased PTHR1 expression in the phalangeal
enchondromas.
The number of genomic aberrations (chapter 7) in phalangeal enchondromas is small, both
in size and number. Unfortunately, phalangeal chondrosarcomas and enchondromas located
elsewhere could not be investigated, due to the lack of fresh frozen material and fragmentation
of the DNA in parrafin blocks due to decalcification, thus a comparison at the genomic level
could not be made.
Combining these results, the better prognosis of phalangeal chondrosarcomas (i.e. low risk
of metastasis) could be partly due to the downregulation of the PTHLH signaling.
Downregulation of PTHLH and BCL2 is also observed in osteochondromas, the benign
counterparts of secondary peripheral chondrosarcomas. It therefore may be a representation
of benign behavior. However, most enchondromas display active PTHLH signaling. Also
the smaller number of genomic alterations in phalangeal enchondromas, as compared to
chondrosarcomas grade I-II with similar histological features, may partly cause the better
prognosis. However, studies of genomic aberrations in phalangeal chondrosarcomas would
be required to test this hypothesis. In contrast, RNA expression levels of phalangeal
enchondromas suggest that these tumors have malignant features, comparable to grade I-II
chondrosarcomas, with which these tumors share several histological features. However, no
data were available for non-phalangeal enchondromas, and therefore we cannot exclude that
these tumors have overall expression levels comparable to the grade I-II chondrosarcomas.
Together these results support both the theory that the more indolent clinical behavior has a
molecular origin reflecting a different biological make up (lower PTHLH expression, low
number of genomic aberrations), as well as the theory that the location is the most important
cause for the better prognosis (RNA expression levels of phalangeal enchondromas are in
line with of those of chondrosarcomas grade II located elsewhere).
IV.b. Enchondromatosis
Enchondromatosis is defined by the presence of multiple enchondromas at different sites.
We investigated whether tumors in this context have different molecular features compared
to solitary tumors. These results then may give clues to the underlying molecular defect and/
or explain the less malignant behavior of these tumors in patients with enchondromatosis.
In the chapters 4-7 tumors of patients with enchondromatosis (Ollier disease, Maffucci
syndrome) were investigated. In chapter 4 we looked for the presence of a previously reported
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mutation in PTHR1 (c.448C>T, p.R150C). We collected enchondromas and chondrosarcomas
from 31 enchondromatosis patients from three different European countries. Screening for
this specific mutation in 26 patients did not reveal the presence of it, nor did direct sequencing
of all coding regions of PTHR1 result in any other mutation. In chapter 7 we investigated
the presence of large genomic aberrations (>~1Mb) in four tumors of patients with Ollier
disease. Although individual tumors showed aberrations, none of these were present in all of
the investigated Ollier disease-related tumors and none were specific for Ollier disease.
With the studies in chapters 4 and 5 we excluded that differences in the PTHLH signaling,
and specifically alterations of the PTHR1 gene were causative for enchondromatosis. RNA
expression studies (chapter 6) revealed only small non-significant differences comparing
three Ollier disease related grade II chondrosarcomas to four solitary grade II
chondrosarcomas, although some genes listed in may become significant, if tested on larger
groups
So, in all non of our studies significant differences were found between enchondromatosis-
related tumors and solitary tumors, suggesting that in both occasions the same pathways are
affected.
The cause of enchondromatosis is still unknown. The syndrome is not hereditary and the fact
that in some patients only certain parts of the body are affected (for instance only right side,
upper body, etc), suggest that the cause of these syndromes lies in early development. In that
case, in the early stages a single cell could be affected, for instance by a mutation. This cell
could than potentially grow out to cells populating one part of the body (mosaicism, reported
for McCune-Albright syndrome, OMIM #174800). Subsequently these cells could be more
vulnerable for a second hit which would be required for the development of enchondromas
(Figure 8.2). Further research will be required to test this hypothesis. To identify the cause of
enchondromatosis it could be investigated as was done for McCune-Albright syndrome. The
gene (GNAS1) causing this was identified by searching for an hereditary syndrome, displaying
similar biochemical and clinical features. This was the case for Albright hereditary
osteodystrophy, for which causative mutations had already been identified. Unfortunately,
although in case of Enchondromatosis some hereditary syndromes are known, but these
Figure 8.2: Hypothesis regarding mosaicism and enchondromatosis. In the early embryogenesis a first genetic hit
takes place, of which the mechanism is unknown, causing the alteration of one of the cells. The embryo continues
to expand with only part of the body affected by this genetic alteration, in this example one of the lower extremi-
ties. A second hit, of which the mechanism is also unknown, will subsequently result in the formation of enchondro-
mas/central chondrosarcomas. This second hit would only result in enchondroma formation if it occurs in regions
in which the first genetic alteration is present. A third hit will result in malignant transformation, creating a (low-
grade) chondrosarcoma. Abbreviations: EC: enchondroma; CS: chondrosarcoma
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have an even lower incidence than Ollier disease or Maffucci syndrome. Therefore, clues of
what is causing enchondromatosis are most likely to be found by genome wide analysis of
RNA or protein expression of a larger group of Ollier disease-related tumors.
V. Concluding remarks and directions for future research
The purpose of this thesis was to investigate the molecular processes involved in development
and progression of enchondromas and conventional central chondrosarcomas, including the
subgroups of those arising in patients with Ollier disease and in the phalanx.
Within these groups, though clearly clinical differences are observed between the three
different subgroups (Ollier disease–related, phalangeal localization and solitary non-
phalangeal tumors), no clear molecular differences are observed. Ollier-disease-related tumors
showed no significant differences from solitary tumors. Phalangeal lesions showed a decrease
of PTHLH expression in only a subset of the phalangeal chondrosarcomas.
Our aim was to further elucidate the multi-step model and identify diagnostic and prognostic
markers.
We constructed a multi-step model, showing  alterations as described in this thesis regarding
malignant transformation, progression and correlation with adverse prognosis. We identified
protein expression of JUNB as a candidate diagnostic tool, showing increased expression in
(low-grade) chondrosarcomas compared to enchondromas. Related with prognosis we found
upregulation of PTHLH signaling in high-grade chondrosarcomas and upregulation of
glycolysis-associated genes combined with downregulation of genes involved in the oxidative
phosphorylation in high-grade chondrosarcomas.
Our genome wide analysis at DNA and RNA level pointed to the candidate genes RPS6 and
CDK4, which are the subject of continuing research, to unravel their role in the pathogenesis
of enchondromas and conventional central chondrosarcomas.
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Chondrosarcomen zijn kwaadaardige kraakbeen-producerende tumoren. Deze tumoren zijn
zeldzaam en groeien meestal langzaam. Het merendeel behoort - microscopisch gezien - tot
de subgroep conventionele chondrosarcomen. Binnen deze groep worden er 3 graden van
maligniteit onderscheiden (graad I-III). De tumoren met de hoogste graad hebben een slechtere
prognose. Binnen de groep van conventionele chondrosarcomen zijn twee groepen te
onderscheiden op basis van waar deze zich bevinden ten opzichte van het bot waarvan ze
uitgaan en al of niet bestaan van een goedaardige voorloper. Het perifere chondrosarcoom
dat altijd ontstaat aan het oppervlak in de kraakbeenkap van zijn goedaardige tegenhanger
het osteochondroom, en het centrale chondrosarcoom dat primair centraal in het bot gelegen
is en kan al of niet ontstaan zijn in een goedaardige voorloper, genaamd enchondroom. Deze
centrale chondrosarcomen zijn het meest voorkomend (± 80%). Dit proefschrift concentreert
zich op deze specifieke groep tumoren.
Enchondromen zijn meestal solitair, dat wil zeggen dat er per patiënt maar één tumor wordt
gevonden. Er zijn echter patiënten waarbij meerdere van deze tumoren voorkomen. Deze
mensen lijden aan een syndroom genaamd “enchondromatose”. Binnen dit syndroom wordt
er onderscheid gemaakt tussen verschillende subtypen waarvan Morbus Ollier (M. Ollier)
en het Maffucci syndroom het meest voorkomend zijn.
Naast graad is ook de lokalisatie in het skelet van de tumoren van belang voor de prognose.
De tumoren gelegen in de botten van de vingers en tenen tonen, in tegenstelling tot wat hun
histologie doet denken, een relatief gunstige prognose.
I. Expressie analyse van central chondrosarcomen
Het onderliggend mechanisme van de ontaarding van enchondromen naar laaggradige
chondrosarcomen is onbekend. Ook zijn er geen moleculaire merkers bekend die kunnen
helpen om het verschil tussen deze benigne en maligne tumoren te verduidelijken. Dit zou
goed van pas komen omdat het verschil soms moeilijk vast te stellen is door de patholoog.
Daarnaast is het histologische graderingsysteem wat wordt gebruikt voor deze tumoren niet
altijd glashelder, doordat de histologische kenmerken die van belang zijn voor de gradering
verschillend geïnterpreteerd kunnen worden.
Chondrosarcomen zijn een van de weinige mesenchymale tumoren waarbij progressie in
graad kan plaatsvinden. Het bestuderen van expressie niveaus in de verschillende graden
kan daarom aanwijzingen geven wat betreft de mechanismen die betrokken zijn bij dit proces
van progressie en de daaraan gecorreleerde risico’s op metastase en tumor gerelateerd
overlijden.
I.a. Specifieke (hypothese gerelateerde) expressie analyse
RNA en eiwit expressie is onderzocht in de hoofdstukken 3 (CDKN2A), 5 (IHH en PTHLH
signaal transductie) en 6 (JUNB).
I.a.1. CDKN2A
Het gen (CDKN2A) coderend voor het eiwit genaamd p16 (betrokken bij de regulatie van cel
groei en deling en zo genoemd naar aanleiding het molecuul gewicht van dit eiwit) ligt in
113
Nederlandse samenvatting
een regio van het genoom (9p21; een gebied op de korte arm van chromosoom 9, band p21)
dat gedeeltelijk verloren is gegaan in een deel van de centrale chondrosarcomen.
Gecombineerde analyse van zowel het mogelijk verlies van de regio 9p21 en de mate van
eiwitexpressie van p16 liet zien dat verlies van de regio en p16 eiwitexpressie voornamelijk
iets is dat voorkomt in hooggradige chondrosarcomen (hoofdstuk 3). Er is echter geen relatie
gevonden tussen het verlies van p16 eiwitexpressie, het verlies van het stukje genoom 9p21,
of de aanwezigheid van methylering van het gen (een mechanisme dat kan zorgen voor een
verminderde eiwitexpressie). Daarom is er waarschijnlijk een ander, nog niet geïdentificeerd,
mechanisme actief dat leidt tot verminderde expressie van p16. Verlies van het eiwit p16
speelt een rol in de progressie van chondrosarcomen. Dit is een gegeven dat ook beschreven
is bij andere tumoren zoals het rondcel liposarcoom.
I.a.ii. JUNB
JUNB is een van de genen die een klein, maar niet significant, verschil heeft gegeven bij de
vergelijking van M. Ollier gerelateerde graad II chondrosarcomen met solitaire graad II
chondrosarcomen zoals beschreven in hoofdstuk 6. Het eiwit JUNB maakt deel uit van een
familie van transcriptie factoren (factoren die op basis van hun kenmerken het afschrijven
van genen zowel positief als negatief kunnen beïnvloeden), genaamd AP-1. Deze factor
speelt een rol bij de controle van groei en differentiatie van kraakbeen. Muizen waarbij JunB
experimenteel is uitgeschakeld laten een gereduceerde groei van zowel kraakbeen als
botvormende cellen zien.
Bij de analyse van JUNB eiwitexpressie in een grotere groep tumoren - opgesplitst in solitaire
en M. Ollier gerelateerde tumoren - is er echter geen verschil gezien tussen deze twee groepen.
Er is wel een verschil gevonden in eiwitexpressie tussen enchondromen en laaggradige
chondrosarcomen. Hierbij is een toename van expressie geconstateerd in de chondrosarcomen.
Dit suggereert dat JUNB expressie mogelijk kan worden gebruikt om het onderscheid tussen
enchondromen en laaggradige chondrosarcomen te maken.
I.a.iii. IHH en PTHLH signaal transductie
In de hoofdstukken 1 en 2 wordt de signaaltransductie regelkring zoals die beschreven is
voor Indian Hedgehog (IHH) en parathyroid hormoon-gelijkend hormoon (PTHLH)
geïntroduceerd. IHH komt aan zijn naam omdat wanneer een eiwit dat er veel op lijkt, in de
fruitvlieg word verwijderd dit leidt tot een larve met allemaal stekeltjes (engels: “hedgehog”),
de naamgeving Indian komt van het feit dat dit gen als eerste werd ontdekt in India. De IHH/
PTHLH regelkring speelt een belangrijke rol in de normale groei en ontwikkeling van de
groeischijf. In erfelijke osteochondromen, de goedaardige tegenhangers van perifere
chondrosarcomen, is de signaaltransductie van deze regelkring beïnvloed door mutaties in
de genen EXT1 en EXT2. Daarom zijn de expressie niveaus van moleculen betrokken bij
deze regelkring in enchondromen en centrale chondrosarcomen bestudeerd in hoofdstuk 5.
De moleculen zijn bestudeerd op eiwit niveau (immunohistochemie) voor PTHLH, PTHR1
(de receptor voor PTHLH), BCL2 (een eiwit betrokken bij het geprogrammeerde sterfproces
van de cel), p21, cycline D1 en cycline E (drie eiwitten betrokken bij de regulatie van de cel
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deling). Op RNA niveau is er gekeken naar IHH, PTCH (patched, de receptor van IHH),
SMOH (smoothened, een eiwit dat vast kan zitten aan PTCH en een rol speelt bij het doorgeven
van het signaal) en GLI2 (een eiwit dat codeert voor een transcriptie factor en eveneens een
rol speelt bij het doorgeven van het signaal)(Figuur 5.1). De data laten zien dat de IHH
signaal transductie regelkring afwezig is in enchondromen en centrale chondrosarcomen,
terwijl de PTHLH regelkring wel actief is. Er is geen verschil in expressie niveaus gevonden
tussen enchondromen en graad I chondrosarcomen. Het lijkt er dus op dat de PTHLH
regelkring geen belangrijke rol speelt in de overgang van enchondroom naar chondrosarcoom.
Een hoger expressie niveau correlerend met toenemende hogere histologische graad is
gevonden voor de eiwitten PTHR1 en BCL2. Dit suggereert dat deze eiwitten mogelijk een
rol spelen in de tumor progressie.
I.b. Algemene gen expressie analyse
In hoofdstuk 6 zijn de RNA expressie niveaus van duizenden genen tegelijkertijd in
enchondromen en centrale chondrosarcomen gemeten, met cDNA microarray analyse. De
progressie is onderzocht door het vergelijken van de expressie patronen per gen in graad I en
graad III chondrosarcomen. Naast de veranderingen die al bekend zijn, zoals de afname van
extracellulaire matrix genen (graad III chondrosarcomen zijn celrijker en hebben minder
substantie liggen tussen de tumor cellen) werden er ook andere processen die significant
verschillend zijn tussen de graad I en graad III chondrosarcomen gevonden.
Een van deze processen is de energie huishouding. In graad III chondrosarcomen is er een
lagere expressie van genen gevonden betrokken bij de oxidatieve fosforylering. Dit is een
proces dat zorgt dat suikers samen met zuurstof (aëroob) worden omgezet in energie. Daarnaast
is er in hooggradige tumoren een hogere expressie gevonden van genen betrokken bij de
glycolyse. Glycolyse is het proces waarbij suiker wordt omgezet in energie, zonder dat er
zuurstof wordt gebuikt (anaëroob). De toename van glycolyse is beschreven bij verschillende
kanker soorten, en er wordt zelfs gesuggereerd dat het een kenmerk is van invasieve tumoren.
De stimulering van het proces van glycolyse leidt mogelijk in de laaggradige tumoren tot
een groeivoordeel, aangezien er in deze tumoren weinig bloedvaten (en dus zuurstof) aanwezig
zijn. Bij toename in graad neemt ook de vaatingroei toe, waardoor er meer zuurstof beschikbaar
is voor de cellen. De glycolyse die netto resulteert in minder energie per suiker molecuul,
gaat echter niet omlaag. Waarschijnlijk zijn de cellen dus omgeschakeld van aërobe naar
anaërobe energie voorziening tijdens progressie. Mogelijk leidt de verhoogde activiteit van
de glycolyse tot een verlaging van de activiteit van de oxidatieve fosforylering. Andere
verklaringen zijn dat tumorcellen de producten die vrijkomen bij de glycolyse nodig hebben,
dat het proces van oxidatieve fosforylering niet goed functioneert (bijvoorbeeld door mutaties),
of dat cellen de hoeveelheid vrije radicalen (een bijproduct van oxidatieve fosforylering dat
het DNA aan kan tasten) willen beperken.
II. Genetische veranderingen in centrale chondrosarcomen
Tot nu toe waren er weinig specifieke veranderingen van het genoom bekend in het geval
van enchondromen en conventionele centrale chondrosarcomen (9p21, 12q). Vorige studies
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combineerden vaak de conventionele centrale chondrosarcomen en de perifere
chondrosarcomen, waardoor mogelijke verschillen specifiek voor een van deze twee groepen
moeilijk te detecteren zijn.
In hoofdstuk 3 is, gebaseerd op eerdere studies, het verlies van de regio 9p21 verder
bestudeerd. Verlies hiervan lijkt specifiek te zijn voor conventionele centrale
chondrosarcomen. De regio bevat onder andere het gen CDKN2A, wat codeert voor het p16
eiwit (zie boven). Doordat het eiwit in sommige gevallen de ontwikkeling en groei van
tumoren kan belemmeren, is dit gen vaak het doel van het verlies. Met behulp van 4 merkers,
gelokaliseerd op chromosoom 9 rondom de regio waar het CDKN2A gene ligt, is aangetoond
dat een kopie van deze regio is verloren in 15 van 39 chondrosarcomen. Er zijn geen mutaties
in de genen CDKN2A en p14ARF (een gen dat gedeeltelijk overlap vertoont met CDKN2A)
gevonden in alle 47 geteste tumoren. Dit alles te samen suggereert dat dit gebied, met de
genen CDKN2A en p14ARF, niet het doel van het verlies is, maar dat er in deze regio (9p21)
een ander gen van belang is.
In hoofdstuk 7 wordt beschreven hoe over het gehele genoom onderzoek is gedaan met
array-CGH (een experiment waarmee de mate van winst of verlies van het genetisch materiaal
in een keer kan worden meten). Er is gekeken naar genomische afwijkingen in primaire
tumoren: enchondromen, graad I, graad II en graad III chondrosarcomen. Hierbij is een
toename in zowel het aantal als de uitgebreidheid van de veranderingen in tumoren van
hogere graad gevonden. In het algemeen waren de afwijkingen van de enchondromen (alle
drie gelokaliseerd in de botten van vingers en tenen) en de graad I chondrosarcomen beperkt
en indien aanwezig klein, hoewel één van de enchondromen verlies vertoonde van geheel
chromosoom 6. In de hooggradige chondrosarcomen zijn beduidend meer, schijnbaar
willekeurige, veranderingen waargenomen, alsof het genoom van deze tumoren instabiel is
geworden.
Geen van de veranderingen was aanwezig in alle geteste tumoren, maar er zijn wel
veranderingen die werden gevonden in meerder tumoren. Door het toepassen van een
scheidslijn waarbij minimaal 5 tumoren dezelfde veranderingen moeten bevatten zijn er 22
regio’s geïdentificeerd. De grootte van deze regio’s varieerde van 0.55 Mb tot 113 Mb. Enkele
van deze regio’s zijn eerder genoemd in andere studies, terwijl andere nog niet eerder waren
gerapporteerd. In het geval van de chromosomen 7, 12 en 20 zijn meerdere stukjes met
verlies of winst gevonden. Op chromosoom 7 zijn dat de regio’s 7p12.3-p15.3, 7p11.2-q11.23,
7q36.1-q36.3, op chromosoom 12: 12p13, 12p11.21-p11.23 and 12q13 en op chromosoom
20: 20q11.21, 20q12, 20q13.33. Verdere analyse toonde aan dat winst of verlies van sommige
chromosomen of chromosoom regio’s specifiek lijken te zijn voor progressie of prognose.
Verlies van chromosoom 6 of 10 en winst van de regio 12q12 correleert met een hogere
graad. Verlies van chromosoom 10 (10pter-10q25.3), 4q13, 4q34.3 en toename van 9q34
correleert met een slechtere prognose.
Winst van genetisch materiaal op chromosoom 12 wordt waargenomen in meerdere
tumorsoorten. Vooral in sarcomen, zoals osteosarcomen en liposarcomen, worden amplificaties
van de regio 12q13-15 vaker gezien. In dit gebied liggen onder andere de genen CDK4,
MDM2, SAS en genen van de familie van “high mobility group” eiwitten. Winst van de korte
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arm van chromosoom 12 (12p) wordt ook gezien in andere typen kanker, zoals bepaalde
types kiembaan tumoren van de testis en pancreas carcinomen. In beide type tumoren wordt,
net als in chondrosarcomen, amplificatie van 12p11 gevonden. Winst van 12p wordt gezien
als een mogelijke stap naar verdere kwaadaardige progressie.
Uiteindelijk zijn de resultaten van de cDNA expressie array (hoofdstuk 6) en die van de
array-CGH (hoofdstuk 7) gecombineerd om te zien of het niveau van de gen expressie mee
verandert met het verlies of winst van gedeeltes van het genoom. Er zijn twee genen
geïdentificeerd, CDK4 (12q13) kwam hoger tot expressie in tumoren waarvan deze regio
amplificatie vertoonde en RPS6 (9p21.3-p24.1) had lagere expressie niveaus in tumoren met
verlies van deze regio. Deze data suggereren dat de hiergenoemde genen kandidaat zijn als
doelwit voor de gevonden winst en respectievelijk verlies.
III. Model voor tumorvorming
Met behulp van de hierboven staande data is een model voor tumor vorming van conventionele
central chondrosarcomen opgesteld (Figuur 8.1).
Bij de transformatie van enchondroom naar laaggradig chondrosarcoom wordt een toename
van expressie van het eiwit JUNB gevonden (hoofdstuk 6). De progressie van laag- naar
hooggradig chondrosarcoom wordt gekenmerkt door de verhoogde expressie van genen
betrokken bij de glycolyse, gecombineerd met de afname in expressie van genen betrokken
bij de oxidatieve fosforylering (hoofdstuk 6). Daarnaast wordt een toename van PTHR1 en
BCL2 eiwitexpressie gezien met toename in histologische graad (hoofdstuk 5), terwijl de
eiwitexpressie van p16 afneemt (hoofdstuk 3). Op genomisch niveau worden er geen
verschillen waargenomen tussen enchondromen en laaggradige chondrosarcomen. Bij de
overgang van laag- naar hooggradige tumoren wordt verlies van chromosoom 6, 10 en
amplificatie van de regio 12q12 gevonden, hoewel verlies van chromosoom 6 ook is gevonden
in één van de drie enchondromen. Tevens nam het aantal en de grootte van de genomische
veranderingen toe in de hooggradige tumoren, mogelijk door genomische instabiliteit
(hoofdstuk 7). Het verlies van 4q13, 4q34, en 10pter-10q25 en de amplificatie van 9q34
bleken te correleren met een slechtere prognose (hoofdstuk 7).
IV. Conventionele centrale chondrosarcoma subtypes
Binnen de groep van conventionele centrale chondrosarcomen zijn er, gelet op de klinische
data, verschillende subtypes te onderscheiden. Patiënten met chondrosarcomen gelokaliseerd
in de botten van de vingers en tenen hebben een lagere kans op uitzaaiingen vergeleken met
patiënten waarvan de tumoren soortgelijke histologische kernmerken vertonen, maar die
elders gelokaliseerd zijn. Ook voor patiënten met enchondromatose, gekarakteriseerd door
meerdere centraal in het bot gelegen kraakbeen-vormende tumoren, worden er als gevolg
van verschillend klinisch gedrag andere histologische criteria gebruikt, vergeleken met
solitaire tumoren.
IV.a. Tumoren gelokaliseerd in vingers en tenen
117
Nederlandse samenvatting
In de hoofdstukken 5 en 6 zijn de RNA- en eiwit-expressieniveaus van tumoren gelokaliseerd
in vingers en tenen (hieronder groep I genoemd) in zichzelf vergeleken met de tumoren die
zich elders in het skelet bevinden (hieronder groep II genoemd). Dit is gedaan om te
onderzoeken of de tumoren biologisch verschillend zijn, of dat de locatie van deze tumoren
in vinger en tenen de oorzaak is van hun goede prognose.
Wat betreft eiwitexpressie (hoofdstuk 5) zijn vanwege de overeenkomsten in de histologie
de chondrosarcomen in groep I vergeleken met graad II chondrosarcomas uit groep II. In
totaal zijn 64 enchondromen (waarvan 21 behoren tot groep I) en 89 chondrosarcomen
(waarvan 17 behoren tot groep I) onderzocht op verschillen in de IHH en PTHLH signaal
transductie regelkring. Er zijn geen significante verschillen gevonden tussen de
chondrosarcomen van groep I en de graad II chondrosarcomen uit groep II. Er was echter
wel een kleine groep van chondrosarcomen gelokaliseerd in de botten van vinger en tenen
(groep I) die verminderde expressie toonden van het eiwit PTHLH. De BCL2 en PTHR1
eiwitexpressie van enchondromen uit groep I waren hoger wanneer deze werden vergeleken
met enchondromen uit groep II (hoofdstuk 5).
RNA expressie analyse is met behulp van cDNA microarray analyse (hoofdstuk 6) uitgevoerd
op 3 enchondromen van groep I en 19 chondrosarcomen uit groep II. Over het algemeen
bevonden de expressie niveaus van de enchondromen uit groep I zich tussen die van de
graad I en graad III chondrosarcomen.
In hoofdstuk 7 is aangetoond dat het aantal genomische veranderingen in enchondromen uit
groep I beperkt is, zowel in grootte als in aantal.
De verminderde expressie van de PTHLH die enkele van de tumoren uit groep I vertonen
zou dus een oorzaak kunnen zijn van hun relatief gunstige prognose. Een aanwijzing dat er
mogelijk een biologisch verschil ten grondslag aan het verschillend klinisch gedrag zou
kunnen liggen is de geringe hoeveelheid genomische veranderingen.
IV.b. Tumoren in de context van enchondromatose
Enchondromatose wordt gekenmerkt door de aanwezigheid van meerdere enchondromen op
verschillende locaties in één patiënt. Gedurende dit onderzoek is in hoofdstuk 4-7 onderzocht
of de tumoren van patiënten met enchondromatose verschillende moleculaire kenmerken
hebben ten opzichte van solitaire tumoren. Deze resultaten zouden mogelijk aanwijzingen
kunnen geven die leiden tot het vinden van de oorzaak van dit syndroom. Daarnaast zou er
mogelijk een verklaring gevonden kunnen worden voor feit dat de histologie een slechte
voorspeller is voor gedrag in patiënten met enchondromatose.
In hoofdstuk 4 is gekeken naar de aanwezigheid van een eerder in de literatuur beschreven
mutatie in het gen PTHR1 (c.448C>T, p.R150C). Hiervoor zijn enchondromen en
chondrosarcomen van 31 patiënten uit drie verschillende Europese landen verzameld die
gediagnosticeerd waren met enchondromatose. De hierboven genoemde mutatie is niet
gevonden in 31 (100%) van de geteste patiënten, noch is er enige aanwijzing gevonden voor
aanwezigheid van een andere mutatie in dit gen. In hoofdstuk 7 is de aanwezigheid van
grote genomische veranderingen (>~1 Mb) onderzocht in 4 tumoren van patiënten met M.
Ollier. Hoewel er in de individuele tumoren wel veranderingen zijn gevonden, waren geen
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van deze aanwezig in alle onderzochte tumoren, noch waren er specifieke afwijkingen in
tumoren in de context van M. Ollier.
Met behulp van de onderzoeken zoals beschreven in de hoofdstukken 4 en 5 zijn er geen
aanwijzing gevonden dat veranderingen in de PTHLH signaaltransductie regelkring, of
specifiek veranderingen in het PTHR1 gen, verantwoordelijk zouden zijn voor het ontstaan
van enchondromatose. RNA expressie studies (hoofdstuk 6) lieten zien dat er alleen zeer
kleine (niet significante) verschillen zijn tussen graad II tumoren van patiënten met M. Ollier
en solitaire graad II tumoren, hoewel sommige van deze verschillen mogelijk wel van betekenis
zouden kunnen zijn als de groepen groter zouden worden gemaakt.
Uiteindelijk is er in geen van de uitgevoerde experimenten een verschil gevonden tussen
enchondromatose gerelateerde tumoren en solitaire tumoren, wat erop wijst dat in beide
gevallen dezelfde regelkringen zijn aangedaan.
De oorzaak van enchondromatose is nog altijd niet bekend. Het syndroom is niet erfelijk en
het feit dat in sommige patiënten alleen bepaalde gedeeltes van het lichaam zijn aangedaan
(bijvoorbeeld alleen de rechterkant) suggereert dat de oorzaak mogelijk in de vroeg
embryonale ontwikkeling ligt. In dat geval zou in een vroeg stadium één cel kunnen
veranderen, bijvoorbeeld een mutatie. Deze cel zou potentieel kunnen uitgroeien tot cellen
die deel uitmaken van een bepaald deel van het lichaam wat ook wel mosaicisme genoemd
wordt. Dit fenomeen wordt waargenomen bij andere aandoeningen zoals het McCune-Albright
syndroom. De veranderde cellen zouden kwetsbaarder zijn voor een volgende verandering
die zou kunnen leiden tot de ontwikkeling van enchondromen (Figuur 8.2). Nader onderzoek
is nodig om deze hypothese te testen. De mutaties in het gen verantwoordelijk voor het
McCune-Albright syndroom werden ontdekt door het zoeken naar klinische en biochemische
overeenkomsten tussen dit syndroom en erfelijke aandoeningen. Hierbij kwam men uit bij
Albright osteodystrophie, waarvan de veroorzakende mutaties reeds bekend waren. In beide
aandoeningen bleek een en hetzelfde gen aangedaan te zijn namelijk GNAS1.
Helaas zal het moeilijk zijn om op dezelfde manier te werk te gaan in het geval van
enchondromatose. Hoewel er wel overeenkomsten zijn met erfelijke aandoeningen, zijn deze
syndromen nog zeldzamer dan M. Ollier of het Maffucci syndroom. Daarom is het
waarschijnlijker dat de oorzaak zal worden gevonden aan de hand van uitgebreide studies
naar RNA en eiwit expressie niveaus gebruikmakend van een grotere hoeveelheid M. Ollier
gerelateerde tumoren dan in dit proefschrift gebruikt zijn.
V. Conclusies  en samenvatting
Het doel van dit proefschrift was het onderzoeken van de moleculaire processen betrokken
bij de ontwikkeling en progressie van enchondromen en conventionele centraal-gelegen
chondrosarcomen, inclusief de subgroepen van M. Ollier gerelateerde tumoren en die
gelokaliseerd in de botten van vingers en tenen.
Hoewel er duidelijk klinische verschillen te vinden zijn tussen deze subgroepen (M. Ollier
gerelateerd, tumoren gelokaliseerd in de botten van vinger en tenen en de solitaire tumoren
elders) zijn er geen duidelijke verschillen op moleculair niveau. Tumoren geassocieerd met
M. Ollier zijn op moleculair niveau niet significant verschillend van solitaire tumoren. In het
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geval van de tumoren van vingers en tenen vertoonde een gedeelte van de tumoren een
verminderde PTHLH eiwitexpressie.
Ons doel was het verder verduidelijken van een stapsgewijs model voor tumorvorming en
het identificeren van diagnostische en progressie gerelateerde moleculaire kenmerken.
Er is een model voor tumorvorming gemaakt, waarin de veranderingen aangaande maligne
transformatie, progressie en die gerelateerd aan slechtere prognoses, zoals gevonden in dit
proefschrift zijn verwerkt (Figuur 8.1). Gerelateerd met transformatie is een verhoogde
eiwitexpressie van JUNB gevonden in laaggradige chondrosarcomen ten opzichte van
enchondromen. Een slechtere prognose (en hogere histologische graad) gaat gepaard met
hogere expressie niveaus van eiwitten in de PTHLH regelkring, alsmede hogere expressie
van glycolyse geassocieerde genen gecombineerd met verlaagde expressie van oxidatieve
fosforylering gerelateerde genen.
De analyse van de genomische veranderingen gecombineerd met de uitgebreide RNA
niveau analyse leidde tot de identificatie van de kandidaat genen RPS6 en CDK4. Deze
genen maken deel uit van verder onderzoek, om hun rol in de pathogenese van
enchondromen en conventionele centrale chondrosarcomen te verduidelijken.
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Color pictures
Figure 3.2: Light micrograph showing the immunohistochemical nuclear and cytoplasmic localization of INK4A/
p16. (A) Positive staining of INK4A/p16 in a grade II conventional central chondrosarcoma. (B) Some conven-
tional central chondrosarcomas showed focal positive INK4A/p16 staining. (C) Fifteen per cent of the conven-
tional central chondrosarcomas were entirely negative for INK4A/p16 staining; the inset shows the internal posi-
tive control of the tumour (endothelial cells)
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Figure 4.1: Immunohistochemical staining for the PTHR1 protein. Sample 22.1, an enchondroma of the phalanx,
showing positive PTHR1 expression in both nucleus and cytoplasm of tumor cells. The endothelial cells, serving as
an internal control, also show PTHR1 expression. A: 50x, B: 100x.
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Figure 5.2: Lack of PTHLH expression in a subset of phalangeal chondrosarcomas. (A) PTHLH expression is
absent in a phalangeal chondrosarcoma, with a positive internal control (inset), while (B) strong expression of
PTHLH is found in grade II chondrosarcoma
Figure 5.3: Immunohistochemical staining for BCL2 and PTHR1 in low- and high-grade conventional central
chondrosarcoma. PTHR1 (A, B) and BCL2 (C, D) staining shows low intensity and a low percentage of positive
cells in grade I conventional central chondrosarcomas (A and C, arrows), while increased staining is found in
high-grade conventional central chondrosarcomas (B and D, grade III)
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Figure 6.3: JunB protein expression in enchondromas and central chondrosarcomas. JUNB immunohistochemi-
cal (nuclear) staining demonstrates JunB expression to be absent or very low expressed in enchondromas (A),
with positive internal controls (inset). Chondrosarcomas were positive in about 50% of the cases (B, grade I
chondrosarcoma, with arrow pointing to double nucleus). Original magnification 40x
Figure 7.2: Hierarchical clustering of the four clones of chromosome 12 differentiating between grade II and
grade III chondrosarcomas. Two clusters, one containing mainly grade III (amplified) samples and the other one
containing grade II chondrosarcomas, can be discerned
